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ABBREVIATIONS 
AChR     Acetylcholine receptor  
AIRE     Autoimmune regulator 
APC     Antigen-presenting cell 
BSA     Bovine serum albumin 
c-KIT     Tyrosine-protein kinase kit or CD117 
CSF1     Colony-stimulating factor 1 
DAPI     4’,6-Diamidino-2-phenylindole dihydrochloride 
DC     Dendritic cell 
DMEM     Dulbecco’s Modified Eagle’s Medium  
DMSO    Dimethylsulfoxide 
DNA      Deoxyribonucleic acid 
dNTP      Desoxyribonucleosidtriphosphate 
EDTA     Ethylenediaminetetraacetic acid 
EGFR     Epithelial growth factor receptor   
EMT     Epithelial-mesenchymal transition  
ERK      Extracellular signal-regulated kinase  
FACS     Fluorescence-activated cell sorting 
FDA     U. S. Food and Drug Administration 
FLT3     FMS-like tyrosine kinase 3 
FOXN1    Fork head factor N1 
GAPDH    Glyceraldehyde 3-phosphate dehydrogenase 
GAD56    Glutamate decarboxylase 56 
GIST     Gastrointestinal stroma tumor 
H2Ax     H2A histone family member X 
HRAS     Transforming protein p21 
HRP      Horseradish peroxidase  
Hsp27    Heat shock protein 27  
IGF-1R    Insulin-like growth factor 1 receptor 
IHC     Immunohistochemistry 
IR     Insulin receptor 
LRP4     Lipoprotein receptor-related protein 
MAPK     Mitogen-activated protein kinase 
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MHC     Major histocompatibility complex 
MSP R 
mTEC     Medullar thymic epithelial cell 
MTS 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide  
MuSK     Muscle tyrosine kinase 
OS     Overall survival 
p53     Tumor protein p53 
PBS     Phosphate-buffered saline 
PCR      Polymerase chain reaction 
PDGFα    Platelet-derived growth factor a  
PDGF R b    Platelet-derived growth factor receptor b 
PFS     Progression-free survival 
PI3K/Akt     Phosphoinositid-3-kinase/ protein kinase B 
qRT-PCR    Quantitative reverse transcription PCR 
RCC     Renal cell carcinoma 
RIPA      Radioimmunoprecipitation assay buffer  
RNA     Ribonucleic acid 
RPM     Rounds per minute 
RPMI      Roswell Park Memorial Institute 
RET     RET proto-oncogene 
SRI     Sunitinib response index 
siRNA     Small interfering RNA 
TC     Thymic carcinoma 
TH     Thymoma 
TKI     Tyrosine kinase inhibitor 
TSCC     Thymic squamous cell carcinoma 
TP53     Tumor protein P53 
TYRO3    Tyrosine-protein kinase receptor  
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1 INTRODUCTION 
1.1 The Thymus 
1.1.1 Development and structure 
The thymus (from the Greek word θυμός, thymos) is a primary lymphoid organ 
responsible for the maturation of T cells. The thymus develops from the ventral 
endoderm of the third pharyngeal pouch and is located in the anterior mediastinum, in 
front of the heart and behind the sternum. The mature thymus shows a lobular 
structure, and each lobe is made up of a central medulla and a peripheral cortex. Under 
the influence of forkhead factor N1 (FOXN1), cortical and medullar epithelial cells 
develop from an endodermal precursor cell. Cortical epithelial cells are characterized 
by the expression of CD205, „major histocompatibility complex“ class II (MHCII), 
thymus proteasome and different cathepsins (e.g. cathepsin L). Medullar epithelial 
cells are CD205-negative and express e.g. CD40 und claudin 41, 2. Epithelial cells in 
the medulla are more densely packed than in the cortex. In addition, there are 
hypercellular squamous epithelial structures called Hassall's corpuscles that most 
likely represent terminally differentiated medullar epithelial cells3 (Figure 1).  
 
 
 
Figure 1: Low power view shows the lobular architecture of the thymus of a young child 
(a). The darker cortex (Ct) is dominated by small lymphocytes, while in the lighter 
medulla (M), epithelial cells predominate. Numerous Hassall’s corpuscles of different 
sizes are located in the medulla (arrow) (b). 
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1.1.2 Function and involution 
As a primary lymphatic organ in all higher vertebrates, the thymus plays a critical role 
in the establishment of a functional repertoire of mature T cells, and is therefore a 
central component of the adaptive immune system. The most important function of the 
thymus is the establishment of a T cell repertoire that effectively protects against 
infection but also tolerates self-antigens. In addition to thymic epithelial cells, dendritic 
cells (DC) and macrophages belong to the so-called professional antigen-presenting 
cells (APC) and are distinguished by constitutive expression of the MHCII and the 
ability to present bound antigens to T cells. The two most important steps during T cell 
development are the so-called positive and negative selection. During positive 
selection, T cells recognize MHC on APCs and survive. T cells that do not recognize 
MHC antigens will die of neglect. Positive selection takes place in the thymic cortex. 
Negative selection occurs mainly in the thymic medulla and is a process in which T 
cells that bind the MHC-antigen complex with too high affinity are eliminated as 
potentially autoreactive. Both cortical and medullary epithelial cells represent 
heterogeneous cell populations with different functions. The ectopic or promiscuous 
expression of tissue-specific self-antigens is a central function of medullary thymic 
epithelial cells (mTECs). A subgroup (5-10%) of mTECS positive for the autoimmune 
regulator AIRE express about 3,000 genes from brain, liver, kidney, pancreas and 
other organs. About 98-99% of all immature thymocytes are eliminated in the thymus, 
and only about 1% with a medium receptor affinity receive a survival signal, leave the 
thymus and move to the periphery4, 5. 
Thymic involution begins already between the ages of 5-10 and is completed between 
the 5th and the 6th decades6. At this time, the thymus consists of about 95% fatty tissue. 
However, the residual 5% thymus remains active until old age. Thymic involution is 
presumably determined by genetic and hormonal factors7. The switching off of the 
homeodomain transcription factor Meis1, which is highly expressed in immature 
mTECs and contributes to the maintenance of a progenitor phenotype and the down-
regulation of FOXN1, seem to be essential. Castration delays or even inhibits 
involution in animal models. The interaction with thymocytes also seems to be crucial 
for the conservation of the thymus, since experimental T cell depletion results in thymic 
involution7. With increasing age, thymic involution leads to a decreased export of 
mature naive T cells from the thymus to the periphery. Starting with the 4th decade of 
life, the thymus is no longer able to fulfil the need for new T cells, and its T cell 
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repertoire dwindles.  This leads to the replacement of old peripheral T cells through 
homeostatic proliferation instead of new T cells from the thymus. Among other 
changes, senescent T cells downregulate CD28 and become resistant against 
apoptosis. T cells thereby begin to express genes that are normally expressed in 
natural killer cells which belong to the innate immune system. In addition, senescent 
cells have the tendency to produce increasing amounts of pro-inflammatory cytokines 
and reduce the response to regulatory signals. This increases the risk of inflammatory 
tissue damage5 
 
1.2 Myasthenia gravis 
Myasthenia gravis (MG) is an autoimmune disease that develops through the 
production of different autoantibodies against proteins of the neuromuscular end plate. 
The symptoms of MG consist of a fluctuating muscle weakness with remission and 
exacerbation, which can first manifest itself as ocular MG in the form of double images 
and ptosis. The most important antigen targets against which autoantibodies are 
directed are the acetylcholine receptor (AChR; about 80% of all cases), the muscle 
tyrosine kinase (MuSK; about 10%) and the lipoprotein receptor-related protein (LRP4;  
about 5%). Autoimmune antibodies against AChR are found in three different clinical 
settings: in patients before the 5th decade with so called early-onset MG, in patients 
over 60 with so-called late-onset MG, and in patients of any age with thymoma (so-
called paraneoplastic MG. The etiology of autoimmune reactions against AChR is not 
known, but certain genetic factors such as HLA-B8 DRB1*03, DQA1*0501 and  
DQB1*0201 as well as risk alleles of PTPN22 und TNIP1 may contribute to 
hyperinflammatory reactions of the thymus8, 9. 
 
1.3 Thymic malignancies 
About 25% of all mediastinal tumors are malignant. 65% are epithelial tumors, divided 
into thymomas (TH) and thymic carcinomas (TC) (50% of cases), followed by 
lymphomas (25%), neuroendocrine tumors (15%), and germ cell tumors (10-15%)10, 
11. TH are subclassified into the more indolent types A, AB and B1, and the more 
aggressive types B2 and B3. TC are further subclassified into squamous cell, basaloid, 
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lymphoepithelioma-like, neuroendocrine and many other types. The differentiation 
between TH and TC is based on morphological, biological and clinical factors. The 
neoplastic epithelium in TH still contains functions of the normal thymic epithelium and 
interacts with immature T cells. Therefore, the immunohistochemical identification of 
immature T cells is an important clue to the diagnosis of a TH. All TH types have  
malignant potential and can recur locally and 128￼. Currently, two alternative staging 
systems are in use: the older Masaoka-Koga system and the more recent UICC TNM 
classification (Table 1). 
 
1.3.1 Thymoma 
1.3.1.1 Type A thymomas 
At about 12% of all thymomas, Type A TH represents the smallest group. The median 
age is 64 (8-88) and males seem to be a bit more frequently affected than females13. 
Histologically, there are different growth patterns (fascicular, storiform, adenoid and 
glomeruloid)14, and they can occur next to each other in one tumor. Hassall bodies are 
not found, and there are no or only few immature T cells. Cases with >10% of the tumor 
area containing a moderate or high content of TdT-positive immature T cells are 
classified as Type AB TH. The epithelial component of Type A TH is strongly positive 
for CK19 and p63 and negative for CK20, CD5 and CD117. Complete resection is the 
therapy of choice and is usually feasible. The 10-year survival rate ranges between 
80-100%. Metastases are observed, but are very rare12, 15. 
 
1.3.1.2 Type AB thymomas 
Type AB thymomas contain a lymphocyte-poor (type A) and a lymphocyte-rich (type 
B) component in varying proportions. In 20-40% of cases, type AB is the most common 
TH subtype. The median age is 57 (11-89). Genetic alterations are more frequent in 
type AB than in type A TH, but there may be a relationship between the two. In type 
AB (and A thymomas), GTF2I mutations are frequent (74%). 20-40% of the cases are 
associated with myasthenia gravis and almost 95% of the tumors are in Masaoka-Koga 
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Table 1: Staging after Masaoka-Koga and after UICC TNM (8th edition, 2017) 16. 
Stage Masaoka-Koga ITMIG  
I Grossly and microscopically 
encapsulated. Also called a non-
invasive thymoma because it has not 
spread beyond the thymus. 
T1a: Encapsulated or unencapsulated, 
with or without extension into 
mediastinal fat 
II The thymoma extends beyond the 
capsule (outer boundary of the thymus) 
and into the nearby fatty tissue or to the 
pleura (outer covering of the lung). 
Sometimes divided into: 
T1b: 
 
Extension into mediastinal pleura 
IIa Microscopic transcapsular invasion T2: Infiltration of the pericardium 
IIb Macroscopic capsular invasion T3: Infiltration of one of the following 
structures: Lung, brachiocephalic 
vein, superior vena cava, chest wall, 
phrenic nerve, hilar (extrapericardial) 
pulmonary vessels 
III Macroscopic invasion of neighboring 
organs. The thymoma extends into the 
neighboring tissues or organs of the 
lower neck or upper chest area, 
including the pericardium (covering of 
the heart), the lungs, or the main blood 
vessels leading into or exiting from the 
heart. 
T4: 
 
Infiltration of one of the following 
structures: Aorta, arch vessels, main 
pulmonary artery, myocardium, 
trachea, or esophagus 
IVA Pleural or pericardial dissemination. 
The thymoma has spread widely 
throughout the pleura and/or 
pericardium. 
  
IVB Hematogenous or lymphatic 
dissemination. The thymoma has 
spread to distant organs 
  
 
 
stage I or II at diagnosis. Higher tumor stages are associated with atypical histological 
features, e.g. necrosis. The epithelial component expresses keratins and p63, and in 
20-30% CD20. The ki67 index is usually <10%. The lymphocytic component contains 
mainly CD3- and TdT-positive immature T cells with a high ki67 index. Complete 
surgical resection is the treatment of choice. The 10-year survival rate ranges between 
80 and 100% with very few documented metastases14. 
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1.3.1.3 Type B1 thymomas 
Type B1 thymomas closely resemble normal thymus with extensive cortical and 
medullary areas with or without Hassall bodies. They represent about 18% of all cases 
and occur slightly more frequently in women. The median age is 57 years of age (6-
83). Coughing, thoracic pain and dyspnea are typical symptoms in two-thirds of the 
patients. 35-45% of the cases are associated with myasthenia gravis. Almost 90% are 
in Masaoka-Koga tumor stage I or II at the time of diagnosis. Infiltration of neighboring 
organs and metastases are very rare events. Over 90% of all type B1 TH are locally 
resectable, and a recurrence is rare, resulting in a 10 to 20-year survival rate in 85-
100% of patients14. 
 
1.3.1.4 Type B2 
Type B2 thymomas are lymphocyte-rich epithelial tumors with a high risk of 
intrathoracic recurrence. They make up about 25-30% of all cases and are evenly 
distributed between females and males. The median age is 50 years with only single 
cases described in adolescents and children. In contrast to normal thymus or type B1 
TH, cortical differentiation is slightly reduced in type B2 TH, and medullary 
differentiation is clearly less developed. About half of the cases are accompanied by 
myasthenia gravis. About 30% are diagnosed as stage III and 10% as stage IV. Distant 
metastases (Masaoka-Koga stage IVb) are observed in about 3%. Type B2 TH 
express numerous keratins (e.g. AE1/3, CK19) and p63. The superimposed 
lymphocytes are mainly immature, CD3/TdT-positive immature T cells. Complete 
surgical resection is the therapy of choice and can be achieved in about 70-90% of 
cases. The recurrence rate of totally resected tumors in Masaoka-Koga stage II after 
10 years is about 32%, and 41% for tumors in stage III. Therefore, postoperative 
radiotherapy is recommended for all stage III tumors. Multimodal concepts with 
preoperative chemotherapy followed by resection and postoperative radio-
chemotherapy of primary non-resectable tumors are recommended. The overall 10-
year survival rate is between 70-90%14, 17.  
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1.3.1.5 Type B3 thymomas 
Type B3 thymomas are predominantly epithelial thymic tumors with rare but mostly 
immature T cells. The neoplastic epithelial cells show an extensive loss of the cortical 
and an almost complete loss of the medullary differentiation. They comprise up about 
15-20% of all cases and men are a slightly more frequently affected than women. The 
median age is 55 years (8-87). Most patients come to clinical attention through local 
symptoms such as thoracic pain or vena cava superior syndrome. 40-50% of the cases 
are associated with myasthenia gravis13. 50% of the tumors are diagnosed as 
Masaoka-Koga stages I and II, about 30% as stage III, and about 20% as stage IV. 
Type B3 TH often show infiltration of neighboring structures such as great vessels, 
pericardium, or lung. The tumor epithelium expresses various cytokeratins such as 
CK19, CK5/6, CK8/18 und p63 plus focally EMA. In contrast to Type A and AB TH, 
CD20 is not expressed, and CD5 and CD117 are also usually negative. The sparse 
lymphocytes are predominantly immature TdT-positive T-cells. The therapeutic 
concepts are the same as for Type B2 TH. Up to 30% of the cases show a recurrence 
after some years and the 10-year survival rate is 50-70%5. 
 
1.3.2 Thymic carcinoma (TC) 
Like TH, TC are also tumors of the thymic epithelium. In contrast to TH, the neoplastic 
epithelium in TC has usually lost its organotypic properties and is not able to mature T 
cells. This is believed to be the reason why TC are not associated with myasthenia 
gravis. The discrimination between TC and TH is of great clinical relevance. In most 
published cohorts, TC had a much worse prognosis than thymomas. In contrast to 
thymomas, which virtually never show lymph node metastases, regional lymph node 
metastases are observed in about 30% of TC18. TC also have a high risk of distant 
metastases (about 50%), whereas thymomas tend to be limited to the thoracic cavity 
and only metastasize outside the thorax in about 15%. The incidence of TC is 1 in 10 
million inhabitants per year and elderly males and females are equally affected. TC are 
further subclassified into squamous cell, basaloid, lymphoepithelioma-like, 
neuroendocrine and many other subtypes. The therapy of TC is in principle the same 
as for thymomas, but it has been shown that postoperative radiotherapy of R0-resected 
stage II tumors results in improved progression-free (PFS) and overall survival (OS)19. 
R1-resected TC should be treated with postoperative radio-chemotherapy. Apart from 
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the resection status, the Masaoka-Koga stage is also considered a prognostically 
relevant factor with a 10-year survival of 60% in stage I vs. 15% in stage IV20. 
 
1.3.3 Molecular pathology of TH and TC 
The histological classification of the WHO of TH and TC has been shown to correlate 
with clinical risk factors such as tumor stage, clinical behavior, and prognosis, 
suggesting an increasing mutational load from type A to TC 21. However, even though 
multi-omics platform analyses of 117 TET demonstrated a marked prevalence of a 
thymoma-specific mutated oncogene, GTF2I, in type A and AB TH, TH and TC were 
among the tumors with the lowest mutational burden of all adult cancers. Rare tumor- 
relevant mutations such as HRAS, NRAS, TP53, even when present, are not 
targetable22. A previous study described an almost mutually exclusive loss of 13q in 
B3 and TC at a frequency of 15% which was associated with disease progression, and 
another group found a rare but also clinically relevant loss of 9p21.3 encoding p16INK4 
and p14ARF in B3 and TC23, 24. Gain of 1q containing the anti-apoptotic MCL1 gene 
was observed in 51% of all subtypes, with a higher frequency in B3 (70%) and TC 
(57%). A copy number gain in the BCL2 locus (18q21.33) with a frequency of up to 
42% in TC is also present in type A and B3 TH. The overexpression of Bcl-2 correlates 
with decreased survival in TET, which is why targeting Bcl-2 has been suggested as a 
combinatorial treatment25. TC also seem to be enriched for mutations in epigenetic 
regulatory genes, among them TP53 which is found in 30-40% of the cases. The 
mutation correlates with an increased IHC staining and is of prognostic relevance26, 27. 
Rare cases had an activating mutation of the KIT gene with a good response to 
imatinib28. 
 
1.3.4 Treatment and response prediction of advanced thymoma and TC 
Complete resection is the basis for the successful treatment of mediastinal tumors. 
However, in advanced TET, where complete removal is not always possible, patients 
seem to also profit from the decreased tumor load. For Masaoka-Koga stages I and II, 
an expanded thymomectomy (R0 resection) including fat tissue is recommended. 
According to ESMO (European Society for Medical Oncology) and NCCN (Clinical 
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Practice Guidelines in Oncology) guidelines, radiotherapy should be taken into 
consideration for cases of Masaoka stage II. The primary therapy goal for the 
Masaoka-Koga-stages III und IVa/IVb is complete resection. In non-resectable but 
functionally operable TH and TC patients, cisplatin-based regimens such as the PAC 
scheme (cisplatin, adriamycin, cyclophosphamid) or alternative cisplatin-/ etoposid-
based therapies are most often used29. Relapses or progressive disease can be 
expected to occur in 10 – 30 % of all patients. In 20-30% of these patients, objective 
remissions can be achieved by cisplatin-based regimens after relapse-free intervals of 
6-12 months30. Approximately 50 % of patients with an advanced malignant TH or TC 
are candidates for a second-line treatment. Aberrant EGFR, c-KIT and IGF-1R 
signaling and angiogenesis as well as mTOR inhibition have been shown to be 
targetable molecular biomarkers involved in the carcinogenesis, growth and different 
behaviors of thymic tumors. However, whereas sunitinib, somatostatin receptor 
inhibitors, everolimus and anti-IGF1R have shown some specific activity, other agents 
have shown little to no clinical advantages 28 30-34. The variable clinical results suggest 
that a broader approach is necessary to obtain satisfactory therapeutic results in a 
relevant proportion of patients with malignant TETs. 
 
1.4 Sunitinib as a second-line therapy option in TH and TC 
In recent years, multi-tyrosine-kinase inhibitors (TKIs) have been successfully used for 
a broad range of malignant tumors, including renal and liver cancer and melanoma. 
Sunitinib (Sutent, Pfizer) belongs to one of the multi-target TKI that has been approved 
by the FDA for treatment of renal cell carcinomas (RCC)35 and imatinib-resistant 
gastrointestinal stromal tumors (GIST). Sunitinib is a very broad inhibitor that impairs 
cellular signaling by targeting multiple RTKs, including all receptors for platelet-derived 
growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs) 
36. However, it is also known to block the intracellular ATP-binding sites of several other 
RTKs such as VEGF1, VEGF3, FLT3, c-KIT, PDGFα, CSF1, and RET 37. 
Sunitinib also seems to be a good option for second-line therapy in patients with 
metastatic TC38. In an open-label phase 2 trial it was demonstrated that sunitinib was 
active in 26% of the patients with pretreated TC, whereas activity was limited to only 
6% in patients with thymoma (Type B3). Molecular profiling of receptor tyrosine kinases 
known to be sunitinib targets, including PDGFRA, FLT3, and KIT showed somatic 
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variations in 62% of TC, but they were not predictive of response to sunitinib39. In a 
different study, three patients with histologically and immunohistochemically 
comparable TCs that showed no mutations in c-KIT, KRAS, BRAF, or EGFR were 
treated with sunitinib. Screening for activated RTK revealed a heterogenous activation 
of EGFR, EphB2, KIT, IR, RON, Erb4, FGFR2, KIT, IGF1R, RET and Tyro3/Dtk with 
the strongest activation in EGFR, TYRO3/DTK and IGF1R. TC seem to be responsive 
to sunitinib, and the therapy is certainly of some benefit. However, due to the acquired 
resistance and potential toxicities of sunitinib, there is need for more refined 
approaches based on biomarkers and patient selection that will help identify the most 
efficacious treatment39, 40. It is also important to investigate whether patients with 
malignant TH may also benefit from this drug. 
 
1.5 A tyrosine kinase peptide array to predict TKI response 
Aberrant RTK signaling activity occurs in tumors that are more resistant to TKI 
treatment. In consequence, RTK activity arrays should be able to distinguish between 
signatures41. Kinase activity profiling could also be a valuable clinical tool to select TKI 
treatment for patients with advanced cancer, enhancing the efficacy of available drugs 
and facilitating the choice of possible new approaches. The PamChip microarray 
contains 144 tyrosine kinase peptide substrates representing key signal transduction 
pathways (PamGene, Den Bosch, The Netherlands). This technology directly 
measures the mechanism of action of a kinase inhibitor by building the ratio of kinase 
activity in the lysate in the absence of a compound over the activity in the presence of 
a compound. Whether the kinase activity measurement or the application of a phospho 
tyrosine kinase (PTK) microarray for the identification of responders versus non- 
responders is more accurate is still under discussion42-46.  The PamGene array is a 
robust screening method that allows measurement and evaluation of tissue lysates 
from individual patients spiked in with available drugs or drug combinations. Consisting 
of a porous membrane, the lysate is repeatedly pumped through the array, thus 
enabling a ‘kinetic’ measurement of phosphorylation changes over time (Fig. 2). Spot 
intensities on the arrays are derived from an anti-phosphotyrosine antibody that binds 
to the peptide substrates which become phosphorylated by kinases present in the 
sample. By inducing a drug resistance in cell lines, this method allows measurement 
of specific drug resistance phospho-patterns. The resistance pattern can then be used 
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to generate a specific prediction quantifier. This quantifier can be applied to the 
phospho-patterns of patient tissue samples and predicts, to a certain degree, the 
response of the tumors to the specific TKI treatment42 
Figure 2: Schematic representation of a PamChip microarray (PamGene). 144 
15mer polypeptides containing a tyrosine at the middle position (top) are attached to 
the surface of a porous three-dimensional chip (middle). Cell lysate-antibody mixture 
is pumped up and down through the array and increasing phospho antibody signal is 
measured by a high sensitivity camera (bottom). Modified from pamgene.com.
 
1.6 Insulin-like growth factor receptor 1 (IGF-1R)  
The IGF-1R is a transmembrane receptor tetramer consisting of two extracellular 
a-subdomains and two transmembrane b-subdomains that are connected through 
disulfide bonds. The two  a-subunits form the 130-135 kDa ligand binding site and the 
90–95 kDa  b-subdomains contain the tyrosine domains 47. IGF-1R is activated by 
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IGF1 and IGF2. The bound ligand leads to an autophosphorylation of the intracellular 
tyrosine residues of the  b-subdomain. This in turn leads to IGF-1R signaling and to 
an activation of the PI3K/Akt anti-apoptotic signaling pathway. In addition, IGF-1R 
activation results in increased cell proliferation over Shc, Ras, Raf – 1/MEK/ERK 
activation. IGF-1R has been shown to be overexpressed in up to 37% of tumors?? 
cases?? and is amplified in up to 26% in TC. Deregulation of IGF2 is another main 
factor behind intensified IGF signaling 48.  
 
1.7 TYRO3/Dtk 
TYRO3/Dtk belongs to the TAM (TYRO3/Dtk , Axl, MerTK) family of RTKs. Each 
member contains an extracellular domain consisting of two immunoglobulin-like 
domains and two fibronectin type III repeats, a transmembrane portion, and a 
cytoplasmic domain with the tyrosine kinase. The human TYRO3/Dtk is located on 
chromosome 15 and the protein contains 890 amino acids with a predicted molecular 
weight of 97 kDa. Due to post-translational modifications, the actual molecular weight 
ranges between 120-140 kDa49, 50. TYRO3/Dtk has a restricted tissue expression 
profile and has been implicated in various biological functions, including myelination in 
the  brain51. Current data suggest that, like other TAM kinases, TYRO3/DTK functions 
in tumor cells to activate common oncogenic signaling pathways, particularly 
MEK/ERK and PI3K/AKT. However, other downstream pathways are likely to play 
critical roles in tumorigenesis as well. Regulation of cell type-specific effectors 
downstream of TYRO3/DTK has also been reported in specific tumor types, including 
microphthalmia-associated transcription factor (MITF) in melanoma and alpha-
fetoprotein (AFP) in hepatocellular carcinoma50, 52-54. Overexpression of TAMs and their 
major ligand growth arrest-specific factor 6 (Gas6) is associated with more aggressive 
behavior of cancers, poorer patient survival, acquired drug resistance and metastasis. 
A role of TYRO3/DTK in cancer has been discussed since its discovery, particularly 
due to its proven function in cell proliferation and survival in several cancer cells as 
well as its correlation to ligand overexpression with poor prognosis of several tumor 
types, including thyroid cancer. In addition, TYRO3/Dtk has also been implicated in the 
resistance to traditional chemotherapies and molecularly targeted agents50. 
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1.8 Hypothesis 
The FDA-approved TKI sunitinib is regarded as feasible for second-line therapy in  
patients with progressive TH and TC. Even though sunitinib activity in TC is high in 
comparison with other second-line treatments, it has no beneficial effect in the majority 
of TC as well as in almost all malignant TH cases. The acquired resistance and 
potential toxicities connected to this drug underline the need to identify other 
approaches based on biomarkers and patient selection to develop the most effective 
individual treatment protocols 39, 40. Kinase activity profiling has also been proposed as 
a valuable clinical tool for selecting patients with advanced cancers to undergo TKI 
treatment. This would enhance the efficacy of available drugs for a more personalized 
medicine and a more accurate response prediction.  
 
1.9 Aim of the study 
The present study aimed to predict response to sunitinib in patients with advanced TC 
and TH. To this end, we combined phospho RTK and MAPK arrays and a multiplex 
tyrosine phosphorylation assay (PamGene) to detect potential biomarkers. One of the 
goals was to generate a sunitinib response index (SRI) using sunitinib-resistant cell 
lines that can be applied to patient samples. The application of the SRI, the prediction 
of the upstream kinases and the combined analysis with the specific RTK and MAPK 
activity provides important information on the response to sunitinib as well as potential 
new sunitinib targets in malignant TH and TC. 
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2 MATERIAL AND METHODS 
2.1 Chemicals and kits 
2.1.1 Chemicals and reagents 
Tab. 1 Chemicals and reagents 
Product Company 
Annexin V Binding Buffer BioLegend, California, USA 
APC Annexin V  
  
Laemmli Sample Buffer 4x BioRad, München, Germany 
TGS 10x Running Buffer   
  
Ampicillin sodium salt Carl Roth GmbH, Karlsruhe, Germany 
LB medium  
Milk powder  
Ponceau S  
Tris Pufferan®  
Tris hydrochloride (Tris-HCl) Pufferan®  
Sodium chloride (NaCl)  
  
Ethanol (100%) (EtOH) Chemsolute®, Renningen, Germany 
Isopropyl  
Paraformaldehyde  
  
Fetal calf serum (FCS) Gibco, Darmstadt, Germany 
L-Glutamine  
Penicillin / Streptomycin  
RPMI-1640  
Trypsin  
  
Dimethylsulfoxide (DMSO) Honeywell, Bucharest, Romania 
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PBS Dulbecco 10x Merck, Darmstadt, Germany 
Re-Blot Plus Strong Solution 10x  
  
Puregene® Proteinase K Qiagen GmbH, Hilden, Germany 
RNase A Solution  
RNase free water   
  
Xtreme GENE HP DNA Transfection 
Reagent 
Roche, Mannheim, Germany 
  
Tissue-Tek® O.C.T. Compound Sakura Finetek , Leiden, Netherlands 
  
b-Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
DAPI  
IGEPAL® CA-630  
Sodium deoxycholate  
Sodium orthovanadant  
Sunitinib Malate  
Tween® 20  
  
Pierce® 660nm Protein Assay Reagent Thermo Fisher Scientific Inc.,  
Pre-Diluted Protein Assay Standards: BSA 
Set 
Massachusetts, USA 
Protein Ladder  (PageRuler™ Prestained 
Protein Ladder) 
 
Triton® X-100 Surface-Amps® Detergent 
Solution 
 
  
 
 
2.1.2 Consumables 
Tab. 2 Consumables 
Product Company 
Mini-PROTEAN® TGXTM Precast Gels  BioRad, München, Germany 
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Polystrene Round-Bottom Tube (5ml) 
 
Corning®, New York, USA 
Combitips advanced 
Tubes (1.5ml, 2ml) 
Eppendorf AG, Hamburg, Germany 
  
Whatman filter 
 
GE Healthcare, Freiburg, Germany 
Tube (15ml, 50ml) 
 
Greiner Bio-one, Frickenhausen, Germany 
  
PCR tube 8 strip (0.2ml) STARLAB GmbH, Hamburg, Germany 
  
Cell scraper 25cm Sarstedt, Nürnbrecht, Germany 
CryoPure (1.8ml)  
Pipet tips  
Serological pipettes (5ml, 10ml, 25ml)  
 
 
2.1.3 Commercial kits and standards 
Tab. 3 Commercial kits and standards 
Product Company 
DCTM Protein Assay BioRad, München, Germany 
Trans-Blot® TurboTM RTA Transfer Kit, 
Nitrocellulose  
 
  
Muse Count & Viability Kit  Merck, Darmstadt, Germany 
  
Plasmid Midi Kit (25) Qiagen GmbH, Hilden, Germany 
Puregene® Blood Kit  
QIAxcel® DNA Screening Cartridge   
  
Western Lightning® Plus-ECL Perkin Elmer Inc., Massachusetts, USA 
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CellTiter 96® AQueous One Solution Cell 
Proliferation Assay 
Promega, Mannheim, Germany 
  
Proteome ProfilerTM Array, Human 
phospso-RTK Array Kit 
Human Phospho-MAPK Array Kit 
R&D Systems Inc., Minnesota, USA 
 
 
2.1.4 Equipment 
Tab. 4 Equipment 
Product Company 
Sonoplus HD70 Bandelin electronic GmbH&CoKG, Berlin, 
Germany 
  
Incubator Binder, Tuttlingen, Germany 
  
Mini Trans-Blot Cell (WB) BioRad, München, Germany 
Trans-Blot® TurboTM Transfer System  
PowerPac 200   
  
Pipetboy Accujet 1000 Brand, Wertheim, Germany 
  
Centrifuge 5417R Eppendorf AG, Hamburg, Germany 
Centrifuge 5424  
Thermomixer C  
Multipipette plus  
  
Muse Cell Analyzer Merck, Darmstadt, Germany 
  
Microm HM550 Microm International GmbH, Walldorf, 
Germany 
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PamStation 12® Workstation 
Processing Flow-Through PamChip 
arrays 
PamGene, 's-Hertogenbosch, The 
Netherlands 
  
Fusion FX Western Blot Detection 
System 
Peqlab, Erlangen, Germany 
peqSTAR Thermal Cycler  
  
QIAxcel® Advanced Instrument Qiagen GmbH, Hilden, Germany 
  
Vortex Genie 2 Scientific Industries Inc., New York, USA 
Plate reader infinite M200 Pro Tecan Group Ltd., Männedorf, Switzerland 
  
NanoDrop ND-1000 Spectrophometer Thermo Fisher Scientific Inc., Massachusetts, 
USA 
 
 
2.1.5 Software 
Tab. 8 Software 
software company 
ND-1000 V3.8.1 Peqlab 
  
Image J Version 1.52j National Institutes of Health and the Laboratory, 
Bethesda, USA 
  
i-control™ Tecan Trading AG, Männedorf, Schweiz 
Magellan™  
  
Fusion Vilber Lourmat, Collégien, Frankreich 
  
Microsoft Excel Microsoft Corporation, Redmond, Washington, USA 
  
GraphPad Prism 7 GraphPad Software, La Jolla, Kalifornien, USA 
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2.1.6 Buffers and solutions 
Tab. 7 Buffers and solutions 
Buffer/solution Ingredients 
Ponceau S solution 0.1% Ponceau S, 1% Acetic acid (100%) 
diluted in ddH2O 
RIPA buffer 
 
 
Protein lyses buffer  
0.5% Sodium deoxycholate, 1% IGEPAL 
CA-360 (NP-40), diluted in 1x PBS (pH 7.4) 
RIPA buffer, complete x EDTA, 1mM PMSF, 
1nM Sodium orthovanadant 
10x TBS 292,7g NaCl (5M), 4,24g Tris (0.035M), 
0,165g Tris-HCl (0.165M), diluted in 1l 
ddH2O 
TBST 1xTBS, 0.1% Tween® 20, diluted in ddH2O 
 
 
 
2.1.7 Biological material  
2.1.7.1 Human cell lines 
Tab. 9 Human cell lines  
Cell line Type Company 
1889c Thymic carcinoma A kind gift55 of Prof. Ralf J. Rieker, 
Institute of Pathology, University 
Hospital, Heidelberg, Germany 
Caki1 Kidney cancer American Type Culture Collection 
(ATCC), Virgina, USA 
Caki2 Kidney cancer  
HCT116 Colorectal cancer  
MCF7 Breast cancer  
PC3 Prostate cancer  
TAB1 Thymoma type AB Originally published as IU-TAB-155 and 
a kind gift of Prof. Loehrer PJ Sr 
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Department of Medicine, Indiana 
University School of Medicine, USA 
 
2.1.7.2 siRNAs 
Tab. 10 siRNAs 
Product Catalog no Company 
Hs_TYRO3_5 SI00288344 Qiagen GmbH, Hilden, Germany 
Hs_TYRO3_6 SI00288351  
Hs_IGF1R_11 SI05076827  
Hs_IGF1R_12 SI05076834  
AllStar Negative Control siRNA SI03650318 
 
 
 
2.1.7.3 Prokaryotic cells 
E.Coli strain DH5α (Subcloning EfficiencyTM DH5αTM) was purchased from Thermo 
Fischer Scientific Inc., Massachusetts, USA. 
 
2.1.7.4 DNA plasmids 
A human DNA plasmid vector for overexpressing IGF1R (#RG214928) and Tyro3 
(#SC108283) were purchased from Origene. pcDNA3 (#79020) was purchased from 
Invitrogen. 
 
2.1.7.5 Antibodies 
Tab. 11 Primary antibodies 
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Product Species Company 
IGF1R Rabbit Cell Signaling Technology Inc., USA 
Phospho-IGF-1-R Rabbit  
TYRO3 Rabbit  
   
b-Actin Mouse Sigma-Aldrich, Germany 
 
 
 
Tab. 12 Secondary antibodies 
Product Company 
Polyclonal Goat anti-Rabbit  Dako GmbH, Germany  
Polyclonal Rabbit anti-Mouse    
  
Polyclonal Mouse anti-Goat  Santa Cruz Biotechnologies, USA 
 
 
2.2 Clinical patient data and tissues 
Clinical data were used with informed consent of the patients and were generated in 
the participating institutions. Tumors were classified according to the current WHO 
classification of tumors of the thymus11. Histological tumor stage was assessed 
according to the modified Masaoka-Koga classification56. Native samples of the tumors 
in available cases were snap frozen in liquid nitrogen and stored at -80°C until further 
processing.  
44 cases of malignant TH and TC were included in the study (21 male, 17 female and 
6 unknown). The ages ranged from 36 to 78 years (median 54 years). The ages of 10 
patients was uncertain. The specimens were obtained between 1986 and 2017. Two 
patients were diagnosed as Masaoka-Koga stage I, 5 patients as stage II, 9 patients 
as stage III and 16 patients as stage IV. In 12 patients, the Masaoka-Koga stage was 
not available. The specimens consisted of type B1 (1), type B2 (26), type B3 (4) and 
TC (13). MAPK arrays were performed with type B2 (8), type B3 (3) and TC (3). RTK 
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arrays were performed on 33 samples (type B1 (1), type B2 (20), type B3 (3) and TC 
(9)) and Pamgene arrays were performed on type B2 (11), and TC (6). The clinical 
 
Tab 13: Patient samples 
 
TSCC, thymic squamous cell carcinoma; B2,5, B2/B3; B1,5, B1/B2; Survival: month 
 
 patient data of the tissue array	 subjects are shown in Table 2. (see 3.2.4.1 and 
3.2.5.1). The study was approved by the ethics committee of the Medical Faculty 
Mannheim, University of Heidelberg (2013-802R-MA) and University Medical Center 
Göttingen (GÖ 912/15). 
 
 
Patient Nr. SEX TH/TC Diagnosis Tumor MG Masaoka Survival Surviver Recurrent Age RTK array MAPK array Pamgene
1 m TC TSCC primary no 4b 82 yes 69 no yes yes
2 m TH B2,5 primary yes 4a 156 yes yes 66 yes yes no
3 f TC Typ C primary 3 132 no 57 yes yes yes
4 m TC TSCC primary no 2 63 yes yes no
5 m TH B3 primary no 3 36 yes 61 yes yes no
6 m TH B2,5 primary 4b 55 no 58 yes yes yes
7 f TH B2 primary 3 47 yes yes yes
8 f TH B3 recurrence yes 57 yes yes no
9 f TH B2 metastasis 4a 41 yes yes no
10 f TH B3 recurrence 3 192 yes yes 47 yes yes no
11 m TH B2 primary 4a yes yes no
12 m TC TSCC primary 4b 60 yes yes yes no
13 m TH B2 primary yes 46 yes yes no
14 f TH B2 primary 4a 36 yes no yes
15 m TH B2 primary 4a 0 52 yes yes no
16 f TH B2,5 primary yes 3 240 yes 51 yes no yes
17 m TH B1,5 primary no 2 51 yes no yes
18 f TC TSCC primary no 3 132 no 57 yes no yes
19 m TH B2 primary yes 3 47 no 53 yes no no
20 f TC Typ C primary 4 12 yes 45 yes no no
21 m TH B2 primary no 2 108 no 57 yes no no
22 m TH B2 primary yes 4a 57 yes yes 43 no no no
23 m TH B2 primary 1 224 yes 47 yes no no
24 f TH B2,5 primary yes 2 12 yes 71 yes no yes
25 m TH B2 primary no 2 no no yes
26 TC Typ C primary 3 36 no yes no no
27 f TH B2 recurrence yes 73 yes no yes
28 m TH B2 metastasis 4a 53 yes yes 78 yes no no
29 m TC Typ C metastasis yes yes no no
30 TH B3 primary no no yes
31 f TH B2,5 primary 4b 53 yes 69 yes no no
32 f TH B2 primary yes 1 0 38 yes no yes
33 m TH B2 primary 4a 0 47 yes no no
34 f TH B2,5 primary no 60 yes no no
35 m TC TSCC primary 70 yes no no
36 f TC B3/C primary 3 0 60 yes no no
37 f TH B2 primary 56 yes no no
38 m TH B2,5 primary 4a 0 45 yes no yes
39 TC Typ C primary no no yes
40 TH B2 primary no no yes
41 TC Typ C primary no no yes
42 TC Typ C primary no no yes
43 m TH B2,5 metastasis no 4a 30 yes
44 f TH B2 metastasis no 4a 41 yes
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2.3 Methods 
2.3.1 Cell culture and resistance development 
The thymoma cell line TAB1, the thymic carcinoma cell line 1889c, the prostate cancer 
cell line PC3, the breast cancer cell line MCF7 and the colon adenocarcinoma cell lines 
HCT116 and HT29 were cultured in 1650 RPMI with 10% FCS and 1% L-glutamine. 
The renal carcinoma cell lines Caki2 and Caki1 were cultivated in McCoys medium 
with 10% FCS, 1% L-glutamine and essential amino acids. All cells were cultured with 
1% penicillin / streptomycin.  All cells were cultivated at 37°C in a 5% CO2 atmosphere 
in a humidified incubator. For the generation of sunitinib resistance, TAB1 and Caki2 
were subjected to increasing concentrations of sunitinib over 6 to 8 weeks, from 0.5 to 
5 µM, by a stepwise 0.5 µM increase. Starting with 0.5 µM, cells were cultured until 
cell growth was equal to that of wild type control. Then the sunitinib concentration was 
increased by 0.5 µM. Resistance was monitored using an MTS test with 5 µM sunitinib 
against the WT control over 48 h (see section 2.3.2). 
 
2.3.2 Cell viability analysis (MTS) 
Cell viability was measured using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega Corporation). This assay is a colorimetric approach 
based on the activity of the cellular mitochondrial reductase in metabolically active 
cells. The yellow-colored tetrazolium compound of the MTS reagent (3-(4,5-dimethyl-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) is reduced to 
purple formazan in the presence of active mitochondria. The absorbance of the purple 
color can be measured and thus allows a conclusion about the viability of the cell. To 
measure cell viability, equal numbers of cells (e.g. 5,000 – 10,000) were seeded in six 
replicates for each treatment into 96-well flat-bottom plates. Cells attached overnight 
and were subsequently incubated for 48 hours with 5 µM sunitinib. 20 µl MTS reagent 
was added to each well and samples were incubated for 1-3 hours at 37°C. Cell viability 
was determined by measuring the absorbance at 490 nm and reference 655 nm using 
i-control on the Tecan Infinite M200PRO plate reader. The impact of sunitinib on cells 
was calculated by normalizing each value by the mean of the untreated control 
replicates. Relative viability was plotted as a bar graph and significance of treated 
samples were calculated to control using a student t-test.  
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2.3.3 Preparation of cell and tissue lysates for Western blot 
Proteins were isolated from cell cultures and fresh frozen human tissue samples. Cells 
were generally cultured in a 6-well format for protein isolation (see 2.3.1). They were 
then washed with 1 ml PBS and lysed by adding 65 µl protein lyses buffer. The cells 
were scratched off using a cell scraper, the lysate was transferred to an Eppendorf cup 
and then incubated on ice for 30 min. The lysate was centrifuged at 4°C for 30 min at 
14,000 rpm and the protein lysate was transferred into a new tube. For protein isolation 
from human tissue samples, frozen tissue was sliced in 5 µm sections and 5 slices 
were re-suspended and partially homogenized in 100 µl lysis buffer by repeated up 
and down pipetting. Samples were incubated on ice for 30 min and subsequently 
centrifuged for 30 min at 4°C at 14,000 rpm, and the protein lysate was transferred into 
a new tube. All protein lysates were stored at -80°C until further use. 
 
2.3.4 Protein extraction and screening for activated RTKs and MAPK 
Protein lysates for the Proteome ProfilerTM Array (Human Phospho-RTK Array Kit) and 
the Human Phospho-MAPK Array Kit were prepared according to the manufacturer’s 
protocol. 1 x 107 cells collected by trypsinization from a 75 cm2 flask were washed with 
PBS and the remaining PBS was removed before 1 ml lysis buffer (1 ml lysis buffer 17 
with 10 μg/mL aprotinin, 10 μg/mL leupeptin, and 10 μg/mL pepstatin) was added. The 
cell pellet was re-suspended and lysed by pipetting up and down and rocking the 
lysates gently at 2-8 °C for 30 minutes. The samples were centrifuged at 14,000 x g 
for 5 minutes and the supernatant was transferred into a clean tube. Whole tumor 
tissue lysates were prepared from 15 5 µm-thick sections. Lysates were then snap 
frozen in liquid nitrogen and stored at -80°C until further use.  
For the detection of phosphorylated kinases, membranes were blocked and 250 µg of 
protein lysate was incubated at 4°C overnight on the specific array. The membranes 
were washed twice with wash buffer before incubating with an anti-phospho-tyrosine-
HRP detection antibody for 2 hours at RT. For imaging, the Chemiluminescent 
Detection Reagent from the Array Kit was mixed in ratio 1:1. After two additional wash 
steps,the membrane was incubated for 1 min with 1 ml of the reagent mix and imaging 
was done performed using the Fusion FX7 chemiluminescence detection system. The 
“signal intensity” was analyzed using the software ImageJ V1.51 (NIH, Maryland, USA) 
followed by normalization to the reference spot of the membrane. 
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2.3.5 Preparation of cell and tissue lysates for kinase array 
About 3*105 cells were collected by trypsinization in general from a 6-well dish and 
cells were pelleted by centrifugation for 5 min at 800 g and 4°C. For fresh frozen tissue, 
five 10-micron frozen sections were collected from TH and TC patient samples. 
Proteins were extracted in 100 μl ice-cold M-Per lysis buffer (Thermo Fisher Pierce, 
Rockford, IL, USA) containing 1:100 Halt’s protease and phosphatase inhibitors 
(Pierce cats. 78420, 78415, Thermo Fisher Pierce, Rockford, IL, USA). Samples were 
re-uspended in lysis buffer, incubated on ice for 15 min and centrifuged at 14,000 rpm 
for 15 min at 4°C. The supernatant was aliquoted and stored at –80°C.  
 
2.3.6 Protein lysate quantification 
Two different methods to quantify proteins were applied. For lysates containing SDS, 
the Pierce 660nm protein assay reagent (Thermo Fisher Pierce, Rockford, IL, USA) 
was used, for RIPA protein lysates the DCTM protein assay kit (BioRad). Protein 
concentration quantified with the Pierce 660 nm protein assay reagent were calculated 
according to the Pierce™ bovine serum albumin standard pre-diluted set (Thermo 
Fisher Pierce, Rockford, IL, USA). 5 µl protein sample and diluted standard was 
pipetted in duplicates in a 96-well dish. 75 µl of protein assay reagent was added to 
each sample, mixed and incubated for 5 min at RT. The absorbance was measured at 
660 nm using the Tecan reader. The sample protein concentrations were calculated 
according to the formula generated by the linear regression of the diluted standards.  
Protein concentrations of RIPA whole lysates were quantified in a colorimetric Lowry 
assay using the DCTM protein assay kit (BioRad) adjusted to small volumes of protein 
lysate. In this assay, the solution S was diluted 1:50 in solution A. 20 µl of this mixture 
was added to 2 µl of the protein sample in a 96-well plate (Greiner Bio-one) before 200 
µl of solution B was added. Absorbance of each sample was measured in triplicate at 
700 nm using the Tecan Infinite M200PRO plate reader (Tecan) with the corresponding 
software Magellan 7.1. The software calculated the median of triplicates and the 
protein concentrations based on a deposited standard curve algorithm.  
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2.3.7 Multiplex profiling of protein tyrosine kinase substrates 
1 μg of cell lysate and 5 μg of tissue lysate were prepared in 40 μl of a final volume of 
kinase master mix containing the kinase assay buffer (50 mM Tris-HCl pH 7.5, 10 mM 
MgCl2, 1mM EGTA, 2 mM dithiothreitol, 0.01% Brij 35, 1 mg/ml BSA, 12.5 μg/ml FITC- 
labelled PY-20 antibody and 0.4mM ATP) in accordance with the instructions provided 
by the manufacturer (PamGene, 's-Hertogenbosch, The Netherlands). Each sample 
was measured as DMSO control and conducted with 5 µM sunitinib. Profiling of the 
substrate tyrosine phosphorylation from cell lines, malignant TH and TC protein lysates 
was performed with PTK PamChip®4 microarrays on a PamStation®12 (PamGene, 
's-Hertogenbosch, The Netherlands) at 30°C. The software Evolve (PamGene, 's-
Hertogenbosch, The Netherlands) was used for initial sample and array processing as 
well as image capture. Tyrosine phosphorylation was followed over 64 cycles.  
 
2.3.8 Image filtering, data adaptation and SRI prediction model generation 
For sample and array annotation, image gridding, quality control (QC) and for 
phosphorylation-signal quantitation the software package BioNavigatoR (version 6.2; 
PamGene, 's-Hertogenbosch, The Netherlands) were used. Annotated data packages 
were stored in the repository in a project-specific order. The slope of the peptide signal 
intensity across different exposure times (10, 20, 50,100, 200 ms) was multiplied by 
100 and log2-transformed. The resulting per spot value was used for further analyses. 
The sunitinib inhibition was defined as the log2 ratio of the signal obtained for the same 
sample treated and non-treated with 5 uM sunitinib. The inhibition ratios were used for 
all subsequent calculations for generating the prediction quantifier, two-group 
comparison and cell and tissue response prediction57. The prediction classifier was 
established using PLS-DA 58-60, resulting in a sunitinib response-prediction index (SRI). 
 
2.3.9 Upstream kinase prediction 
To predict kinases involved in the sunitinib resistance, significant values of a two-group 
comparative analysis between resistant and non-resistant samples (quantifier, cells 
and tissue) was performed and the significant single values were visualized by a heat 
map. The significant tyrosine phosphorylation sites were subjected to upstream kinase 
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prediction using the upstream kinase operator. This operator within the Bionavigator 
software maps peptides using standard BLAST tools to match the peptides on the chip 
to phosphor sites in the human proteome. The phosphoNET database 
(www.phosphonet.ca) queries kinases that are predicted to phosphorylate these sites. 
Comparing two experimental groups, this information is added to the included peptides 
by enrichment. A significance score Qsp is calculated, including the significance of the 
multiple kinase-associated statistic values (www.phosphonet.ca) The final score Q is 
used to rank the included kinases for putative involvement in the observed 
experimental differences. The top values from the specificity and sensitivity scores 
were considered for further investigation. 
 
2.3.10 Western blot  
WB was performed with 15 µg protein in 4x Laemmli sample buffer (BioRad) containing 
b-mercaptoethanol for denaturation. Samples were denatured at 95°C for 5 min and 
cooled down on ice. Single samples together with a protein ladder (Thermo Fisher 
Scientific) were loaded onto a precast Mini Protein TGX gel (BioRad) in a gel chamber 
with TGS running buffer (BioRad). Protein was stacked at 80 V for 5 min and run at 
250 V. The run was stopped when the blue loading dye reached the end of the gel. 
Proteins were transferred onto a nitrocellulose membrane using the Transfer Kit and 
the semi-dry Trans-Blot TurboTM System (BioRad) with the corresponding programs. 
After blotting the membrane was washed in TBST and the protein transfer was 
visualized by staining the membrane with Ponceau S solution. This dye has a light red 
color that can be used for a rapid reversible detection of protein bands. To avoid 
unspecific binding reactions of the primary antibody the membrane was blocked in 5% 
milk in TBST for 1 h at RT. The membrane was then rinsed with TBST and incubated 
overnight with the primary antibody (Tab. 9) diluted in TBST at 4°C. The membrane 
was subsequently washed three times with TBST and incubated with an appropriate 
secondary antibody (Tab. 10) diluted in TBST for 1 h at RT. The membrane was then 
again washed three times in TBST and covered with an appropriate volume of the 
peroxidase substrate Western Lightning Plus ECL Prime (Perkin Elmer Inc.). Proteins 
were detected using the Fusion FX7 chemiluminescence detection system (Peqlab). 
β-Actin was applied as a loading control in each WB experiment performed. ImageJ 
was used to quantify protein signal intensities.  
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2.3.11 Vector amplification 
Chemically competent Subcloning EfficiencyTM DH5αTM was used to amplify DNA 
plasmids. 25 ng of plasmid DNA, in less than 5 µl H2O, was incubated in 50 µl bacterial 
cell suspension on ice for 30 min. The bacteria were heat shocked at 42°C for 30 sec 
and then placed directly on ice for 2 min. They were then subjected to 1 ml LB medium 
and incubated at 37°C and 450rpm for 1 h in order to recover. The bacteria were then 
added to 50 ml LB medium containing 100 µg/ml ampicillin for selection and overnight 
(16 hours) culture in a 37°C incubator shaking at 225 rpm. A QIAGEN Plasmid Midi 
Kit® was used for enriched plasmid isolation following manufacturer’s instructions. The 
bacteria were harvested by centrifugation at 6000 g for 15min. The pellet was re-
suspended, lysed and the protein was precipitated. The lysate was filtered using a 
Whatman filter and the supernatant was applied to an equilibrated Qiagen-tip 500 
column. After two washing steps, the plasmid DNA was eluted, precipitated in isopropyl 
and centrifuged at 10000 g for 15 min. The pellet was then washed twice in 70% EtOH 
and centrifuged before being air-dried and re-suspended in 8 0µl RNase-free water. 
Plasmid DNA was quantified using the NanoDrop before samples were stored at -
20°C. 
 
2.3.12 Knockdown of IGF1-R and TYRO3/DTK using siRNA  
Cells were transfected with 80 nM siRNA against either IGF1-R (Hs_IGF1R_7, catalog. 
No. SI02624552) or TYRO3/DTK (Hs_TYRO3_5, catalog No. SI00288344; Qiagen) 
using HiPerFect Transfection Reagent (Qiagen) according to the manufacturer's 
protocol. Briefly, 100 µl transfection medium containing 12 µl HiPerFect, 9.6 µl 
siRNA/negative control (20mmol/L), and 78.4 µl RPMI160 medium without FCS was 
incubated at room temperature for 20 min and added to 3*105 cells in 2.3-mLmedium 
just after seeding. Cells were incubated for 24 hours and further processed for 
immunoblot and viability assay. 
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2.3.13 Transfection and overexpression of TYRO3/DTK and IGF1R 
TAB1, 1889c and Caki2 were transfected in 96-well and in 6-well cell culture plates 
(see 3.2.3.1). 100 µl transfection mix was prepared using FCS-free RPMI-1640 
medium, 2 µg of the DNA plasmid and 2 µl X-treme GENE HP DNA Transfection 
Reagent (Roche). The mix was vortexed and incubated for 20 min at RT before it was 
added dropwise to freshly seeded cells using 5 µl/well for 96-well and 100 µl/well for 
6-well cell culture plates. Cells were incubated at 37°C and 5% CO2 concentration. 
Overall, cells were incubated up to 96 h with or without sunitinib treatment (see 3.2.3.3) 
according to the experimental setting. 
 
2.3.14 Reconstitution of IGF1-R and TYRO3/DTK    
Cells were transfected with 1 µg expression vector TYRO3/DTK /Dtk (CAT#: 
SC108283, Origene) or IGF1R (CAT#: RC600009, Origene) using X-tremeGENE™ HP 
DNA Transfection Reagent (Roche) according to the manufacturer's protocol. Briefly, 
100 µl transfection medium containing 1 µg of plasmid DNA 98 µl RPMI160 medium 
without FCS and 1 µl X- tremeGENE was incubated at room temperature for 20 
minutes and added to 3*105 cells. Cells were incubated for 24 hours before sunitinib 
treatment and further processed for immunoblot or viability assay. 
 
2.3.15 Statistical analysis and data presentation 
 
Statistical analysis was performed using GraphPad Prism 7.0d for Mac. Significant 
differences between two groups were calculated using either student’s t-test or the 
Mann-Whitney U test depending on normality of signal distribution, which was 
assessed by the Shapiro-Wilk test. Multiple t-tests were performed using One-way 
ANOVA. Bivariate correlations were carried out using Pearson (for continuous 
variables) or Spearman (for ordinal variables) correlation coefficients. Data are 
presented as mean ± standard error of the mean (SEM), unless otherwise stated. 
Significance values are stated as follows: p  £  0,05 (*), p  £  0,005 (**), p  £  0,0005 
(***).
results  
  32 
3 RESULTS 
3.1 Phospho RTK and MAPK arrays of malignant TH and TC 
An earlier clinical study found that patients responding to sunitinib activate certain 
RTKs, including epithelial growth factor receptor (EGFR), insulin receptor (IR), RET 
proto-oncogene, IGF-1R and TYRO3/Dtk38. Other groups have shown that IGF-1R is 
increased in TC61, and IGF-1R inhibitors have been implicated in clinical trials for TH 
and TC treatment62. Therefore, we first tested the activity of RTKs and MAPKs in 
malignant TH or TC patient samples. We applied tissue lysates from 33 patients on 
phospho RTK arrays and from 14 patients on MAPK arrays as described in Material 
and Methods (Table 1). The arrays were scanned, signals were background corrected 
and normalized to positive controls (Supplement Table 1 and 2). First, we looked at 
the signal distribution of single RTKs in all patients and then sorted out the single RTK 
phospho signals throughout all samples by their intensity. For almost all RTKs, at least  
 
 
Figure 3: Phospho signals and distribution of prominent RTKs in malignant TH 
and TC. Distribution of single phospho signals of EGFR (A), TYRO3/Dtk (B), IGF-1R 
(C), IR (D), PDGFRb (E) and MSPR (F) sorted by intensity. Orange bars mark TC. 
Olive bars mark recurrent or metastatic TH. TH = 24, TC = 9. The distribution of all 
single RTKs is shown in Supplemental Figure 1.  
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one single strong signal was observed in one of the tissue samples (supplemental 
Figure 1), but the RTK activation was heterogeneous in the tumor cohort. The most 
prominent RTKs with a wider range of moderately activated RTKs included pEGFR, 
pTYRO3/Dtk, pIGF-1R, pIR, pPDGFR b and pMSPR (Figure 3A-E). The strongest 
signals were detected for pEGFR, which was present in almost all samples. TC 
(orange bars) showed moderate to strong RTK activation in the six shown samples. In 
contrast, recurrent and metastatic TH (olive bars) showed a strong activation of 
TYRO3/Dtk and MSPR and less activation of EGFR.  
 
3.2 Hierarchical clustering of RTK arrays 
To investigate whether there are subgroups with specific RTK activation within the 
present cohort of TH and TC, we applied an unsupervised hierarchical clustering using 
Morpheus (https://software.broadinstitute.org/morpheus). Data were adjusted by 
quantile normalization and columns and rows were clustered by the average linkage 
method. This resulted in two heterogenous groups that were predominantly defined by 
pEGFR and pTYRO3/Dtk (Figure 4, top). We then took the mean phospho signals of  
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Figure 4: Hierarchical clustering of RTK phosphoarrays and analysis of 
subgroups of activated RTKs. Upper panel: Hierarchical clustering patient samples 
indicated two groups (Cluster 1 and 2) of differentially activated RTKs. Lower panel: 
Cluster comparison of the most dominant RTKs pEGFR (A), pTYRO3/Dtk (B), pIGF-
1R (C), pPDGFRb (D), pMSPR (E) and pIR (F). (n = 33) 
 
a specific RTK and compared the clusters to each other. Using student’s t-test, of the 
6 predominant RTKs a statistically significant difference between clusters 1 and 2 could 
only be shown for EGFR and pTYRO3/Dtk (Figure 4 A-F). IR, pPDGFR   and pMSPR 
did not show a difference in activation. 
To investigate whether the significantly different activity of EGFR and pTYRO3/Dtk 
also correlated to recurrent or metastasized TH (Figure 1), we compared them to  
 
 
Figure 5: Comparison of RTK activity of recurrent and metastatic TH with 
primary TH and TC Comparison of the activity of recurrent/metastatic (dark grey bars)  
and primary tumors (light grey bars) shows a significant difference in activity of 
TYRO3/Dtk and EGFR (G). Relative phosphorylation is represented by the “Signal 
Intensity” as described in Material and Methods. 
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primary TH and TC. This showed that pTYRO3/Dtk was significantly more activated in 
recurrent and metastatic TH, whereas EGFR activity was significantly increased in 
primary tumors. However, pIGF-1R, pPDGFRb, pMSPR and pIR did not show any 
significant differences (Figure 5). 
 
3.3 MAPK arrays of 14 malignant TH and TC 
Due to the limited number of tissue samples, we were only able to performed MAPK 
arrays in 14 samples according to the RTK arrays (Table 1and Figure 6A).  The mean 
phospho values of the MAPK were higher than those of the RTKs (Figure 6B). 
Hierarchical clustering resulted in 2 major groups with 3 distinct clusters (clusters 1-3)  
 
 
 
Figure 6: Hierarchical clustering MAPK arrays to predict differentially activated 
groups. Hierarchical clustering of phospho MAPK signals of patient samples resulted 
in three groups (clusters 1, 2 and 3) (A). The mean MAPK activation was higher than 
the RTK signals, with RSK2 showing the lowest and HSP27 the highest signals (B). 
Comparison of MAPK activity within the clusters. p38d and RSK1 in cluster 1 vs 2/3 (C 
and D) and RSK1 in cluster 2 vs 1/3. 
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(Figure 6A). Comparison of the two main clusters (cluster 1 vs. cluster 2/3) revealed a 
significantly different activity of p38δ and RSK1. Cluster 1 showed a significantly 
stronger activation of p38d and decreased RSK1 activation (Figure 6C and D). RSK1 
was also significantly less activated in cluster 2 (Figure 6E). 
 
3.4 Analysis of clinical data 
To test whether any RTK was related to other available clinical parameters, we 
compared the phospho signals of all RTKs to histological tumor type, MG status and 
Masaoka-Koga stage (Table 1). Do to the rather small groups for the specific 
comparisons this did not reveal any significant differences or correlations.  
 
3.5 Cell lines with different sunitinib response 
To establish an in vitro assay for sunitinib resistance, we then used the TH cell line 
TAB1, the TC cell line 1889c, the breast cell line MCF763, and the colon cancer cell 
lines HT2964 and HCT11665 with published responses to sunitinib. Cells were treated 
with different concentrations (0, 2, 5 and 10 uM) of sunitinib over 120 hours (Figure 7). 
This revealed different growth patterns for each cell line. TAB1 was the least resistant 
cell line with a significant difference in growth for 5µM sunitinib already after 24 hours, 
in contrast to the other cell lines with no significant response until after 48 hours (Figure 
7A and C). 1889c, HTC116 and MCF7 did not develop a significant response to 5 µM 
sunitinib until 72 hours treatment (Figure 7A, D and E). MCF7 seemed to be the most 
resistant cell line even when grown under 10µM sunitinib treatment. Therefore, 5 µM 
sunitinib treatment for 48 hours was used for further experiments. 
 
3.6 Drug dosage and resistance induction of TAB1 and Caki2 
Since TAB1 was the only sunitinib-responsive cell line, there was need of a second 
non-resistant cell line. Recurrent renal cell carcinomas (RCC) are also treated with 
sunitinib as second-line therapy66, and thus RCC cell lines Caki1 and Caki2 were 
tested for sunitinib response. After treating 1889c, TAB1, Caki1 and Caki2 cells with 5 
μM sunitinib for 48 hours, cell growth was significantly reduced in TAB1 and Caki2, 
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Figure 7: Sunitinib treatment of different cancer cell lines over 120 hours. The 
cell lines 1889c (A), TAB1 (B), HT29 (C), HCT116 (D) and MCF7 (E) were tested in 
terms of their response to different concentrations of sunitinib (0, 2, 5 and 10µM) using 
MTS viability assay. Responses were monitored every 24 hours up to 120 hours. 
Asterisks indicate the earliest time point when a significant difference was detected 
with 5µM sunitinib. (n=6) 
 
 
whereas 1889c and Caki1 showed no difference in viability in comparison to untreated 
controls (Figure 8A). To induce resistance to sunitinib, TAB1 (TAB1R) and Caki2 
(Caki2R) cells were cultured under increasing sunitinib concentrations (0.5 to 5 μM) as 
described in Material and Methods. Cells were cultured until a steady growth and 
normal viability was detectable before increasing the sunitinib concentration. 
Resistance induced cell lines TAB1R and Caki2R showed a significant difference to 
native TAB1and Caki2 and an almost equal viability as the resistant cell line 1889c and 
Caki-1 (Figure 8B). 
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3.7 Generation of the sunitinib response index (SRI)  
To predict sunitinib response in patient samples, we generated an index of sunitinib 
response (SRI). For this, we measured TAB1, TAB1R, Caki2 and Caki2R in the 
presence or absence of sunitinib, and to assure equal QC and prediction classifier 
conditions, all measured samples including resistance induced cell lines, native cell 
lines and tissue samples were implemented. Before the sunitinib-DMSO ratio was 
generated, phospho signals of separate sunitinib-treated and DMSO controls were 
visualized (see Supplementary Figure 2A and B, respectively). Visualization and 
unsupervised clustering of the ratio values showed a clear grouping (Supplemental 
Figure 2C). Ratios and inhibition profiles were obtained as described in the Material 
and Methods section. Four resistance-induced, 2 TAB1R and 2 Caki2R as well as four  
 
 
 
Figure 8: Induction of sunitinib resistance in TAB1 and Caki2 and generation of 
sunitinib response index (SRI). TAB1 and Caki2 showed a 20% decreased viability 
after 5 µM sunitinib treatment over 48 hours as compared to 1889c and Caki1. (N= 6) 
(A). Sunitinib resistance induced TAB1R and Caki2R after 5 µM sunitinib treatment for 
48 h (N= 6) (B). Visualization of the prediction quantifier with generated Pam index 
(SRI) from 4 native and 4 sunitinib resistance-induced cell lines (C).  
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corresponding native cell lines were selected to generate the SRI using the prediction 
classifier as described in Material and Methods. This resulted in a prediction classifier 
as shown in Figure 8C. 
 
3.8 Validation of SRI in cell lines 
To validate the SRI, we first tested TAB1, TAB1R, Caki2, Caki2R, 1889c, Caki1, PC3, 
HT29 and HCT116 for their response to 5µM sunitinib after 48h by MTS, and then 
separated the cells according to their relative viability in a responding (orange bars) 
and a resistant group (olive bars) (Figure 9A). The application of the SRI resulted in a  
 
 
 
Figure 9: Validation of SRI on cell lines. Tested cell lines were plotted according to 
their relative viability after sunitinib treatment in comparison to untreated controls. 
Responsive cell lines are orange, resistant olive green (N=6) (A). Representation and 
order of the SRI of cell lines in A. Positive SRI values represent resistance and negative 
SRIs predicted native cells (B).  
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separation of the cell line in two groups, with different indexes. The SRI accurately re-
estimated the resistance-induced cell lines by mistaking one Caki2R. In addition, the 
SRI predicted PC3, 1889c and HCT116 accurately and mis-predicted Caki1, MCF7 
and HT29. These results indicate that the SRI may predict sunitinib resistance to a 
certain degree, but there may be other mechanisms that influence the response to 
sunitinib (Figure 9B). Nevertheless, we performed a hierarchical clustering and an 
upstream kinase prediction of the two predicted groups as described in Material and 
Methods. The top 10 predicted scores were for FLT1, FMS, BRK, FYN, TYRO3/Dtk 
KDR, BMX, TEC, PYK2 and VEGFR3 as predicted kinases (Supplemental Figure 3 
and 4). 
 
3.9 SRI application on tissue samples and upstream kinase prediction 
The in vitro SRI (developed in cell lines) was also applied to 17 malignant TH and TC. 
This resulted in two distinct clusters with potentially responding patients (negative 
values) and a second putative resistant group (positive values) (Figure 10). 
Importantly, one sample came from a patient with TC and liver metastases (pre-  
 
 
 
 
Figure 10: Waterfall plot of SRI prediction of sunitinib response in 17 malignant 
TH and TC samples. The application of the SRI to tissue samples divided TH and TC 
into two distinct groups that can be considered possible responders (negative values) 
and non-responders (positive values). Bars are marked with the TH or TC (R = 
recurrent sample). Sunitinib-responding patient is marked with a red triangle.  
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therapeutic) who was known to have experienced a partial remission and stable 
disease under sunitinib treatment. This patient was predicted to be a potential 
responder (red triangle). The most probable kinases responsible for the difference 
between responders and non-responders in the upstream kinase prediction were 
FGFR1, ALK, TYRO3/DTK, ERBB3, BRK, TEC, PYK2, FGFR2, CTK and TRKB 
(Figure 11A and B, Supplemental Figure 5). 
 
 
Figure 11: Upstream kinase prediction of potentially resistant and responsive 
patients. Inhibition values and specificity score of tissue lysates after SRI application 
(A). Vulcano plot of the upstream kinase prediction of tissue (B).  
 
 
3.10 IGF1R and TYRO3/Dtk for functional testing 
When comparing the upstream predictions of cell lines and tissues, TYRO3/Dtk was 
commonly predicted in the top 5 with a strong specificity score. TYRO3/Dtk has not 
been shown to be a target of sunitinib, but is activated in sunitinib-responsive 
patients40. However, since TYRO3/Dtk was one of the strongest activated RTKs with 
a significance increase in recurrent and metastatic patient samples, it received 
particular focus. IGF-1R was not among the top hits of the upstream kinase prediction, 
but results from earlier studies had shown an increased activity in sunitinib-responsive 
patients. Moreover, inhibition of IGF-1R has already been tested in small clinical 
trials62. IGF-1R is overexpressed in many TH and TC and is a potential target of 
A B
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sunitinib54. Therefore, TYRO3 and IGF-1R were studied further for their relevance in 
the sunitinib response. 
 
3.11 Expression of IGF1R and TYRO3/Dtk in native and resistant cell lines 
We performed WB in lysates of native and resistant cell lines to detect IGF-1R and 
TYRO3/Dtk protein. IGF-1R protein expression was decreased in Caki1R and TAB1R 
but not in Caki2R in comparison to their parental cell lines. Treating Caki2R with 5 µM 
sunitinib even increased IGF-1R protein levels (Figure 13 A, upper panel). TYRO3/Dtk 
levels did not decrease in resistant cell lines in comparison to their native counterparts. 
However, treating resistant cell lines with 5 µM sunitinib almost abrogated TYRO3/Dtk 
signals (Figure 13 A, lower panel).  
 
3.12 IGF-1R and TYRO3/Dtk influence sunitinib resistance in TC and TH cell lines 
To evaluate on a functional level whether low levels of IGF1-R and/or TYRO3/Dtk are 
responsible for the resistance against sunitinib, we knocked down both genes with two 
independent siRNAs separately in the parental cell line TAB1 and Caki2 and 
subsequently treated them for 48 hours with 5 µM of sunitinib. In the case of IGF1R, 
the downregulation in the susceptible parental cell lines significantly increased the 
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Figure 12: IGF-1R and TYRO3/Dtk protein regulation in sunitinib-resistant cell 
lines. IGF-1R protein expression in Caki1R, TAB1R and Caki2R next to parental cell 
lines (A, top). TYRO3/Dtk expression in resistant and native Caki and TAB1 cell lines 
(A, bottom). Transient knockdown with two different siRNAs against IGF-1R induced a 
significantly increased sunitinib resistance in TAB1 and Caki2 (B and C). The transient 
knockdown of TYRO3/Dtk siRNA in TAB1 and Caki2 did not show any effect on cell 
viability after 5 µM sunitinib treatment for 48 hours (n = 3) (D und E). 
 
resistance to sunitinib in all knockdown cases in comparison to mock-transfected cells 
(Figure 12B and C). In contrast, siRNAs against TYRO3/Dtk had no effect on cell 
viability after sunitinib treatment in TAB1 and Caki2 (Figure 12D and E). 
To further analyze the relevance of IGF-1R and TYRO3/Dtk for the (non-)response to 
sunitinib treatment, both genes were overexpressed in TAB1 and 1889c cells. In Caki 
cells, we were not able to sufficiently overexpress either gene (Figure 13A). 
Overexpression of IGF-1R in the resistant TAB1R and 1889c significantly sensitized  
 
 
 
Figure 13: Overexpression of IGF-1R and TYRO3/Dtk in cell lines treated with 
sunitinib. The over expression of IGF-1R in the resistance-induced TAB1R and 1889c 
showed a reduced viability upon sunitinib treatment (C and D). Overexpression of 
TYRO3/Dtk showed no effect in TAB1 and significantly increased the resistance of 
1889c after 48 hours of 5 µM sunitinib treatment (D and E). pcDNA was transfected as 
control vector.  
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both cell lines to sunitinib (5 µM over 48 h) (Figure13B and C). However, the 
overexpression of TYRO3/Dtk in the parental cell line TAB1 did not show any changes 
in the response to sunitinib, but it significantly decreased sunitinib sensitivity (Figure 
13D and E). 
 
3.13 pIGF1-R and TYRO3/Dtk do not correlate with SRI 
We then sought to investigate the correlation between IGF-1R and TYRO3/Dtk and the 
corresponding SRI. Here, WB signals (Figure 14A) and phospho signals from the RTK 
arrays of IGF-1R and TYRO3/Dtk were compared to the specific SRI of the patient 
samples. Unfortunately, this did not result in any relevant correlation (Figure 14B – I).  
 
 
 
Figure 14: Correlation of IGF-1R and TYRO3/Dtk with SRI. WB of TYRO3/DTK and 
IGF-1R of 20 tissue lysates (A). WB signal intensities of TYRO3/Dtk (B) and IGF-1R 
(D) and of RTK phospho signals of TYRO3/Dtk (C) and IGF-1R (E) were correlated to 
the SRI of the specific sample. Comparison of the mean normalized WB signals (F and 
H) or the phospho signals (G and I) of the „responder“ (negative SRI) against  the “non-
responder“ (positive SRI). The correlations (B-E) and differences (F-I) did not reach 
the level of significance. WB numbering corresponds to Patient No. 
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There was a tendency towards an inverse correlation between IGF-1R and the SRI (R2 
= 0,2593, p<0.109) (Figure 14D) and the potential “responding” group showed 
increased IGF-1R levels in comparison to the “non-responder” group (Figure 14H). 
pTYRO3/Dtk even showed a tendency to a positive correlation to the SRI (Figure 14C 
and G). 
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DISCUSSION 
Due to the rarity of TH and TC, very few randomized clinical trials for second-line 
therapies have been possible to date. The treatment options after total resection have 
thus long been limited to radiochemotherapy, but with high tumor recurrence rates. 
Recently, alternative second-line therapeutic options (such as kinase inhibitors) have 
been introduced largely on an empirical level (i.e. without a strong molecular rationale) 
40, and the treatment choice is difficult since the available drugs are active only in a 
minority of patients with a particular histological tumor subtype. Predicting the 
response to therapeutic treatments such as sunitinib is a primary prerequisite of 
personalized medicine and would aid in the choice of treatment. In this study, we used 
RTK and MAPK phospho arrays to characterize the malignant TH and TC by their 
kinase activities and established a sunitinib response index (SRI) using a multi peptide 
array. We further focused on the functional analysis of predicted TYRO3/Dtk and IGF-
1R as potential sunitinib targets and biomarkers for sunitinib response in malignant TH 
and TC. 
RTK phospho arrays from 33 malignant TH and TC revealed EGFR as a highly 
activated kinase in over 70% of the cases. Recent studies in a limited number of 
patients suggested that EGFR antagonists such as cetuximab may provide effective 
treatment in specific cases 30-33. However, the variable findings in these studies 
suggest that a more detailed approach is necessary to obtain better therapeutic results.  
Hierarchical cluster analyses of RTK phospho array analyses revealed two main 
dominant patterns, with either strong activation of EGFR alone or combined with strong 
activation of TYRO3/Dtk. Even though there was no connection of EGFR activation to 
clinical parameters, the significantly higher activation of TYRO3/Dtk in recurrent and 
metastatic tumors activity might be an indicator of disease progression of malignant 
TH and TC. This finding fit to data from several recent studies in which stronger 
TYRO3/Dtk phosphorylation was found to be associated with a worse prognosis in 
various cancer types50, 51.  
Hierarchical clustering of 14 MAPK arrays revealed three rather distinct groups within 
malignant TH and TC: p38d and RSK1 were significantly differentially activated in a 
cluster-specific manner.  
To adapt to environmental changes, cells activate p38MAPKs as one of the main signal 
transduction mechanisms. In mammals, there are four p38MAPK isoforms encoded by 
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different genes: p38α (MAPK14), p38β (MAPK 11), p38γ (MAPK 12), and p38δ (MAPK 
13)67. Particularly p38α, the most studied p38MAPK, has been shown to play a role in 
innate immune responses and inflammation67.The importance of p38γ and p38δ in 
cancers that are associated with chronic inflammation, also recently became evident68. 
In breast cancer, p38γ and p38δ in particular have been found to promote cancer 
progression, invasion and metastasis69, 70. Furthermore, a recent study in a p38γ and 
p38δ knock-out mouse model reported that activation of these specific MAPKs was 
important for early T cell development71. Furthermore, p38 has been linked to MG 
because it increases the expression of IL-6 and RANTES, which is likely to lead to 
pathological remodeling of the myasthenic thymus72. Therefore, p38MAPKs should be 
taken into consideration when studying thymic malignancies including TH and TC, MG, 
thymic inflammation in the elderly, and thymic involution.  
RSK1 has been described in invasive melanoma73 and has been proposed as a 
therapeutic target in triple negative breast carcinoma74. Therefore, it is possible that 
increased RSK1 activity could also indicate a more aggressive phenotype in malignant 
TH and TC.  
In summary, the analysis of the RTK and MAPK phosphorylation arrays revealed 
TYRO3/Dtk as a potential prognostic marker in malignant TH and TC. The activities of 
p38MAPKs and RSK1 are increased in subgroups, but show no prognostic value. 
However, the specific activity of p38 MAPKs and the spectrum of their functions points 
to their potential use for following disease onset to metastasis in TH and TC.   
For a more predictive clinical approach, we utilized kinase activity profiling as a 
potential tool for selecting sunitinib to treat malignant TH and TC. We established a 
sunitinib response index with the resistance-induced cell lines TAB1R and Caki2R in 
comparison to their native parental cells. To increase the discriminative power, and to 
stabilize the technical variances, we used the ratio of the measurement of each sample 
with and without sunitinib added during the assay. A similar approach has been 
published by Arni S. et al., who identified a potential predictive signature by 
characterizing 71 paired early-stage and non-neoplastic lung adenocarcinoma sample 
lysates in the presence or absence of the tyrosine kinase inhibitor gefitinib57. Applying 
the SRI to 8 cancer cell lines, we were able to validate the response in 5 cell lines. To 
increase the specificity of the SRI in the future, a bigger number of sunitinib resistance 
induced cell lines need to be included. Nevertheless, the application of the SRI to 
patient samples separated 17 malignant TH and TC into two well-defined groups: 7 
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potential sunitinib-resistant non-responders and 10 responders, including one long-
term sunitinib-responding patient. A closer look at the potential non-responding group 
revealed 2 samples with a much higher index than the rest (Figure 10). Although these 
samples were not associated with any specific clinical features in the respective 
patients (who were not treated with sunitinib), it is possible that the observed massive 
in vitro resistance might predict sunitinib resistance in vivo. One observation we made 
was that the majority of the predicted resistant samples were TC, whereas on the 
responder side, there was only one known responder TC among the TH. This finding 
is in contrast to the observations described by Thomas et al.39 in which TC patients 
had a higher frequency of response to sunitinib than TH. Further investigations are 
necessary to exclude technical biases or type-specific SRI separation. 
The prediction of upstream kinases responsible for responsive and non-responsive 
phospho patterns identified TYRO3/Dtk as the main RTK and potential sunitinib target. 
This is in agreement with previously published data in patients who responded 
particularly well to sunitinib treatment, showing strong activation of certain RTKs, 
including TYRO3/Dtk 54. A biologic activity of sunitinib on TYRO-3/Dtk has not been 
reported so far. TYRO3/Dtk and the other two known members of the TAM receptor 
family share a conserved sequence within the kinase domain and adhesion molecule-
like extracellular domains, and are involved in many different cellular processes, 
including proliferation and survival, cell adhesion and migration. The TAM receptor 
family members are overexpressed in a variety of human cancers8 and are suggested 
to be potentially oncogenic51. Moreover, TYRO3/Dtk has recently been described as a 
molecular target in bladder cancer. TYRO3/Dtk showed a higher expression than AXL 
and MERTK in muscle-invasive bladder cancer. Bladder tumor cells were sensitive to 
pan-TAM inhibitors, and TYRO3/Dtk depletion led to cell cycle inhibition and 
apoptosis75. Since TYRO3/Dtk also showed a significant association with disease 
progression (Figure 5), we wanted to validate its function with respect to the resistance 
against sunitinib.  
In the course of a sunitinib resistance, development TYRO3/Dtk was downregulated in 
cell lines with induced resistance. Sunitinib treatment of resistant Caki2R and Caki1R 
almost abolished TYRO3/Dtk levels (Figure 12). Knockdown of TYRO3/Dtk did not 
have a remarkable effect the response to sunitinib, but its overexpression in 1889c 
made cells even more resistant to sunitinib treatment (Figure 13). In addition, we found 
that TYRO3/Dtk activity is also increased in progressive TH diseases. This proposes 
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that low activity of TYRO3/Dtk, independent of the protein level, is in addition to the 
SRI a potential predictive biomarker for the response of malignant TH and TC to 
sunitinib. These in vitro results are in contrast to observations in sunitinib responding 
patients and point out that TYRO3/Dtk alone is not sufficient to predict treatment 
response. Therefore, determination of TYRO3/Dtk kinase activity warrants evaluation 
as a predictive biomarker in prospective clinical trials.  Although IGF-1R does not seem 
to have the predictive potential upstream kinase in the current setting, sunitinib has 
previously been shown to be active against IGF-1R26. Furthermore, strong activity of 
IGF-1R in ex vivo biopsies was previously observed in sunitinib-responsive TC 
patients38. 
The knockdown of IGF-1R in the native cell lines TAB1 and Caki2 showed a significant 
decrease in response to sunitinib. The overexpression led to an increased response 
to sunitinib in resistant TAB1R as well as in the TC cell line 1889c. This strongly 
suggests that IGF-1R is involved in the response to sunitinib, and that activation of 
IGF-1R is an indicator for treatment response (Figure 14). 
There are several possible explanations for why we could not show a clear correlation 
between expression and activation of IGF-1R and TYRO3/Dtk with the established 
SRI. The rather small group size is most likely one of the major factors. Analysis of 
RTK and MAPK arrays revealed a large heterogeneity of kinase activity among the 
samples even in the distinct group of malignant TH and TC. An accurate and 
standardized treatment after resection is of importance for future studies to avoid 
degradation bias. 
In summary, in this study, we characterized malignant TH and TC using RTK and 
MAPK activity arrays. This revealed a large heterogeneity of kinase activities, 
particularly concerning EGFR, TYRO3/Dtk and members of the p38 MAPK family that 
were strongly activated in specific subgroups. p38 MAPKs are of specific interest, since 
p38d isoforms might help us understand the origin of the tumor development in 
connection with chronic inflammation. Furthermore, we present a novel, experimentally 
partially validated predictor of sunitinib response in 8 cell lines of malignant TH and TC 
that is based on RTK activity assay. We also validated IGF1-R and TYRO3/Dtk as 
potential biomarkers and possible sunitinib-resistance indicators. Future clinical trials 
should include IGF1R and TYRO3/Dtk for validation of the SRI. 
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4 SUMMARY 
Metastatic and recurrent malignant thymomas (TH) and thymic carcinomas (TC) are 
generally refractory to current empiric radiochemotherapies, thus warranting the 
search for novel second-line therapeutic strategies. The multi-target tyrosine kinase 
inhibitor sunitinib has been shown to induce partial remissions and to prolong overall 
survival of patients with aggressive TH and TC.  However, although sunitinib has been 
proposed as an alternative treatment option in refractory disease, treatment response 
is only partial, and not all patients benefit equally. For a more accurate response 
prediction, new biomarkers are needed. 
In this study, we used phospho receptor tyrosine kinase (RTK) and MAPK arrays as 
well as a multiplex tyrosine phosphorylation assay containing 144 kinase substrates to 
characterize malignant TH and TC and to generate a sunitinib response index (SRI) 
using sunitinib resistance-induced cell lines. The RTK and MAPK arrays stratified the 
patients into two main dominant phosphor patterns: Pattern 1 was characterized by a 
strong activation of EGFR while pattern 2 was typified by a strong activation of 
TYRO3/Dtk. This activation of TYRO3/Dtk correlated with recurrence and metastatic 
spread of malignant TH.  p38d and RSK1 were cluster-specifically activated in the 
MAPKs but showed no specific disease correlation. The SRI was functionally validated 
in several cell lines, and the application of the SRI to native malignant TH and TC 
samples identified a potentially sunitinib-responsive and a potentially sunitinib-
resistant group. Among the predicted upstream kinases, TYRO3/Dtk belonged to the 
top candidates responsible for sunitinib response. TYRO3/Dtk and the highly activated 
IGF-1R in responsive patients were also functionally validated. Specific siRNA 
knockdowns in sunitinib-resistant cell lines and overexpression confirmed the 
functional relevance of TYRO3/Dtk and IGF1-R for sunitinib resistance.  
We present the SRI as a new approach to the resistance prediction of sunitinib in 
malignant TH and TC and propose that the activity level of TYRO3/Dtk and IGF-1R 
could serve as markers to aid in treatment decisions. The results of this in vitro 
investigation need validation of the SRI in prospective clinical trials. 
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6 SUPPLEMENTAL MATERIALS  
Supplemental Table 1: Normalized phospho signal values of RTK arrays. Mean signals 
of double spots were normalized to positive controls after background correction. 
Negative and 0 values were set to 1. Patient Nr. Correspond to Patient sample list (see 
Tab13) 
 
 
 
 
 
 
 
 
Patient Nr. EphA3 EphA2 Flt-3 FGF R4 ROR2 MuSK SCF R EphB1 HGF R VEGF R3 FGF R3 EphA6 EphB4 EphA4 FGF R1 TrkB PDGF R alpha VEGF R1
2 5,11 3,44 1,00 5,36 10,16 0,13 1,00 1,00 33,39 1,00 3,53 10,21 1,00 11,16 2,78 4,79 2,85 1,00
3 1,55 0,29 1,00 1,00 1,91 1,00 5,45 1,40 2,28 1,00 1,00 8,39 1,43 3,07 1,00 0,72 0,00 1,00
4 1,00 1,00 1,00 1,00 2,32 1,00 2,70 2,12 0,27 10,36 15,51 1,00 12,57 6,67 1,00 1,40 1,00 9,47
5 1,00 1,00 1,11 1,00 1,00 1,00 2,12 3,92 1,41 3,56 5,56 6,44 2,62 1,00 1,00 3,51 2,60 2,23
6 2,61 4,26 9,75 6,80 7,34 7,34 6,76 7,19 4,96 9,76 7,08 19,27 5,50 9,91 2,19 7,37 5,30 7,16
7 1,00 1,00 7,34 3,16 3,22 1,39 6,13 2,75 5,54 7,12 8,36 13,42 2,20 1,92 7,29 2,65 4,72 2,59
8 1,00 1,00 1,51 1,00 1,73 1,00 2,94 2,43 4,30 4,66 1,00 59,98 1,00 1,00 8,05 5,47 2,55 1,00
9 3,16 20,31 15,59 6,09 71,45 22,60 7,36 9,70 1,00 33,43 2,34 24,43 8,76 6,87 2,11 7,88 5,17 8,54
10 1,00 1,00 1,00 1,00 3,82 1,00 1,00 2,01 0,31 3,19 1,00 4,57 3,08 0,57 0,19 3,15 0,76 1,23
11 1,00 1,00 109,11 47,37 1,00 68,68 126,55 82,78 58,05 124,03 82,12 67,52 90,80 1,00 105,32 94,47 113,63 104,53
12 1,00 1,00 1,00 1,00 1,00 1,00 1,00 5,09 1,00 1,00 1,00 1,00 1,00 37,14 1,00 1,00 1,00 1,00
13 1,00 1,00 1,00 1,00 1,00 1,00 1,00 17,09 18,81 1,00 1,00 31,71 1,00 1,00 1,00 19,03 5,77 1,00
14 0,25 0,98 2,88 2,54 2,96 2,47 5,68 6,03 9,03 3,35 5,98 11,86 3,62 1,10 7,11 7,07 5,91 3,75
15 8,80 8,37 15,04 23,50 26,98 17,97 17,14 18,68 21,53 23,38 50,16 26,48 15,18 21,57 21,82 22,94 19,44 10,79
16 1,00 1,00 1,00 1,00 4,12 1,00 1,00 1,00 1,00 1,00 3,07 1,00 1,00 1,00 1,00 1,00 1,00 1,00
17 1,00 1,00 3,20 1,45 1,00 2,28 3,00 6,62 1,81 4,22 7,14 14,70 3,78 1,00 1,62 6,11 4,04 3,18
18 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 13,72 0,04 1,00 1,00 1,00 1,00 11,00 1,00
19 1,00 1,00 1,00 1,00 1,00 1,00 175,00 1,00 20,05 1,00 50,42 12,49 1,00 1,35 1,00 1,00 4,45 42,12
20 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00
21 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00
24 6,57 6,31 1,00 1,00 11,64 7,72 1,00 1,00 1,00 9,87 10,25 1,00 1,00 1,00 1,00 1,00 1,00 1,00
26 27,62 72,17 48,66 17,12 1,00 33,05 35,28 0,37 1,00 45,80 35,81 1,00 1,73 51,19 15,93 1,00 81,91 0,63
27 0,62 5,40 4,58 6,76 3,01 15,60 1,00 1,00 1,00 12,13 3,78 1,00 1,00 4,37 1,00 1,00 1,00 1,00
28 7,86 2,24 11,68 5,64 17,10 9,06 11,04 22,57 20,50 20,99 15,42 50,00 7,83 0,40 5,86 22,60 12,04 14,44
29 1,00 3,59 8,04 3,37 4,79 8,37 38,59 1,00 3,62 13,78 11,99 1,00 11,15 2,93 8,67 0,60 5,88 10,80
31 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 0,97 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00
32 5,31 9,42 12,91 15,86 16,16 18,33 19,54 19,98 20,82 20,96 21,10 21,37 21,59 21,71 22,96 23,08 24,45 26,20
33 1,00 0,01 1,29 0,88 4,07 2,80 3,31 1,21 0,19 10,08 11,15 2,86 4,64 1,00 5,72 0,09 3,29 5,26
34 8,65 9,11 1,00 1,00 26,08 1,00 1,00 1,00 1,00 1,00 1,00 1,83 1,00 13,18 1,00 1,00 1,00 1,18
35 8,45 8,17 1,00 1,00 24,29 1,00 1,00 1,00 1,00 4,58 9,27 1,00 1,00 28,81 1,00 1,00 1,00 1,00
36 1,00 0,80 1,00 1,00 23,78 1,00 8,23 13,12 18,49 1,00 23,43 18,80 1,00 1,00 1,00 0,65 1,00 1,00
37 1,00 1,00 13,54 1,00 1,00 1,00 43,42 54,69 52,32 21,78 11,20 56,52 42,54 1,00 46,68 56,69 58,80 53,38
38 9,87 17,95 52,21 50,30 28,86 49,60 62,60 30,68 21,90 62,46 56,26 35,24 51,24 4,31 55,37 29,88 39,38 54,20
TrkC IGF-1 R EphA7 ErbB4 ErbB3 Dtk ROR1 VEGF R2 FGF R2alpha TrkA PDGF R beta Tie-2 Mer ErbB2 Axl c-Ret Insulin R Tie-1 EphB6 M-CSF R MSP R EphB2 EphA1 EGF R
1,00 13,20 7,12 12,18 30,10 15,57 4,48 1,00 1,00 19,14 2,44 22,86 35,26 20,96 11,78 4,32 9,87 16,69 1,00 1,91 18,35 1,00 4,07 181,01
0,89 4,84 4,20 0,06 0,28 3,99 0,92 1,00 1,00 3,96 3,00 8,61 5,18 7,74 5,64 1,67 1,38 3,00 1,00 1,00 0,36 3,28 0,04 124,06
1,00 1,00 2,16 1,00 1,00 13,42 0,09 9,47 1,00 3,46 42,89 1,00 7,21 2,70 1,00 1,00 6,44 6,17 9,08 13,99 2,59 12,15 1,00 192,91
1,58 2,47 4,26 22,71 5,70 107,60 1,23 0,89 3,05 8,04 5,77 8,92 14,79 18,08 1,00 1,00 1,00 0,29 7,92 1,00 13,96 33,96 1,00 54,25
6,57 7,19 13,95 13,64 6,00 84,38 6,67 5,48 7,32 19,01 8,72 18,23 13,02 12,04 5,65 6,22 8,90 16,43 7,95 8,92 14,74 20,26 8,89 28,44
1,65 2,29 5,31 3,92 4,54 9,51 2,04 3,13 7,92 14,81 12,01 13,76 11,78 13,35 1,00 3,72 5,40 7,56 2,72 11,10 5,49 6,11 4,66 124,07
1,91 2,11 34,14 18,98 3,28 105,30 1,06 1,00 16,83 20,52 12,22 54,76 46,02 18,76 1,00 1,00 7,96 3,64 1,00 1,00 23,47 14,02 3,47 90,40
11,49 30,41 42,25 62,62 8,86 163,26 18,00 7,24 12,67 34,17 15,82 88,48 36,71 34,10 64,87 22,50 25,21 11,26 10,49 17,63 177,75 10,72 36,12 73,30
2,63 1,81 5,16 3,41 1,00 52,37 4,24 0,06 3,94 5,67 2,73 10,34 4,96 3,07 2,52 1,98 3,23 3,96 3,27 1,00 9,71 9,16 3,30 12,74
93,15 47,58 127,99 147,26 93,49 135,16 23,73 114,82 129,22 123,30 143,44 79,97 79,82 120,99 1,00 20,88 46,65 1,00 135,02 81,88 144,85 141,88 41,32 107,78
1,00 1,00 1,00 1,00 1,00 16,91 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 19,40 1,00 1,00 1,00 1,00 1,00 137,99
7,72 1,00 27,68 11,72 13,40 1,00 1,00 1,00 1,00 35,27 1,00 31,26 27,79 10,27 1,00 1,00 1,00 1,00 1,00 1,00 25,95 21,81 1,00 193,52
4,50 2,23 9,02 7,22 5,62 7,85 3,62 2,81 7,82 12,44 9,07 21,30 17,94 13,40 0,75 3,00 5,92 4,34 3,00 5,88 8,62 12,28 3,62 167,80
16,35 21,78 20,29 23,20 20,93 31,78 30,23 7,87 22,31 23,71 34,49 25,89 35,67 28,34 36,38 16,58 37,60 27,99 14,13 71,62 41,27 42,34 22,35 188,90
1,00 1,00 1,00 1,00 1,00 6,57 1,12 1,00 1,00 1,00 0,59 1,00 1,00 1,00 3,83 1,00 0,30 1,00 1,00 1,00 1,00 1,00 0,74 13,05
4,64 1,00 8,68 9,99 1,50 84,78 1,00 2,27 3,58 8,73 5,11 10,69 9,15 3,66 0,75 1,00 1,00 1,00 7,13 2,24 10,87 33,60 1,00 21,05
1,00 1,00 1,00 1,00 1,00 2,81 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 132,19
1,00 64,17 24,79 171,00 32,23 1,00 1,00 1,00 1,10 39,02 1,00 43,82 150,32 167,00 2,60 1,00 36,10 1,00 1,00 1,00 27,53 1,00 1,00 204,31
1,00 20,46 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 70,64
1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,12 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 143,93
1,00 25,09 1,00 1,00 1,00 40,83 18,28 1,00 1,00 1,00 26,64 1,00 1,00 1,00 7,68 2,59 80,26 5,32 1,00 20,72 1,00 1,00 14,53 173,96
1,00 99,49 1,00 13,51 1,00 1,00 4,73 17,11 43,30 13,17 133,21 1,00 1,00 64,99 17,81 41,15 74,72 18,28 23,67 15,95 3,55 5,79 80,66 151,61
1,00 22,63 1,00 1,00 1,00 73,43 31,26 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 26,78 24,24 4,08 11,09 20,77 1,00 18,56 34,51 1,00
17,00 4,77 34,46 37,06 8,55 84,23 3,97 9,45 24,32 33,69 22,91 42,49 30,39 21,23 12,80 7,92 12,05 27,01 5,63 12,64 56,78 23,60 11,20 22,45
6,45 5,89 1,00 7,80 3,32 1,00 10,26 9,27 13,94 1,00 17,95 5,95 29,32 8,39 2,99 13,48 28,56 0,31 12,60 17,80 8,17 23,46 12,75 164,23
1,00 1,00 1,00 4,03 1,00 2,08 1,00 1,00 1,77 1,00 1,00 1,00 1,00 1,00 1,00 1,00 1,00 12,96 1,00 1,00 1,00 1,00 1,00 96,41
26,27 26,44 28,17 28,19 28,98 29,34 29,97 30,34 32,71 36,51 38,04 40,28 40,66 41,06 42,25 44,68 44,84 50,77 54,05 54,19 56,48 67,49 71,88 135,36
0,08 7,75 1,37 7,00 1,00 42,97 10,81 1,82 5,88 0,80 28,05 16,62 8,86 5,60 7,21 3,32 18,02 6,79 9,84 6,10 12,70 35,87 9,90 207,17
1,00 27,78 1,00 1,00 1,00 35,62 20,27 1,00 1,00 1,00 28,50 1,00 1,02 11,68 71,56 3,85 17,93 27,38 1,00 1,00 1,00 12,83 12,10 184,04
1,00 58,03 1,00 1,00 1,00 17,77 17,51 1,00 1,00 1,00 8,37 1,00 1,00 1,00 20,92 3,87 12,17 17,61 1,00 89,08 1,00 1,00 4,01 74,96
1,00 49,99 8,05 1,00 1,00 1,00 25,39 0,51 1,00 24,69 34,65 21,34 27,28 1,00 16,36 1,00 29,32 1,00 1,00 8,65 0,14 1,00 1,00 115,89
52,13 1,00 68,31 59,39 48,19 1,00 1,00 50,97 38,98 68,40 60,56 49,85 51,54 72,71 1,00 1,00 1,00 1,00 149,74 1,00 65,52 174,74 1,00 155,18
34,76 43,68 37,79 42,33 28,52 22,26 41,43 61,88 56,91 32,19 75,43 30,09 29,74 29,70 28,76 30,90 52,37 13,71 58,28 64,10 43,10 44,60 32,09 116,65
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Supplemental Table 2: Normalized phospho signal values of MAPK arrays. Mean 
signals of double spots were normalized to positive controls after background 
correction. Negative and 0 values were set to 1. Patient Nr. Correspond to Patient 
sample list (see Tab13) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Nr. RSK2 AKT2 GSK-3 beta p38 gamma p70 S6 Kinase JNK pan Akt pan AKT1 GSK-3 alpha/beta p38 beta Akt3 p38 delta JNK3 JNK1 ERK2 ERK1 p38 alpha MSK2 JNK2 RSK1 HSP27
1 59,58 42,70 52,49 93,40 95,33 57,23 104,02 101,92 70,56 93,29 69,98 116,91 89,33 62,47 96,67 34,15 93,58 90,49 86,55 78,13 88,44
2 3,60 131,62 5,03 135,05 4,07 70,19 115,96 57,75 66,98 2,06 9,68 119,34 2,27 4,86 88,80 138,68 169,46 71,32 61,83 3,69 149,93
3 0,64 1,42 1,00 1,08 1,24 2,06 1,90 0,56 -0,43 82,26 0,44 203,08 4,38 2,66 30,05 66,99 132,72 9,54 6,74 -0,67 112,61
5 4,32 2,36 0,39 12,18 0,45 0,53 2,70 1,53 1,30 6,43 3,98 153,28 2,38 2,92 7,92 9,24 64,06 4,37 5,72 2,16 19,82
11 4,53 11,28 2,20 4,22 6,76 4,99 5,38 19,52 8,44 16,20 41,56 4,54 11,66 17,15 7,98 3,97 41,98 10,36 18,59 76,73 10,05
6 26,44 26,82 31,58 26,70 34,66 39,59 28,51 63,73 53,84 82,48 105,19 33,62 134,67 137,46 145,91 46,14 128,28 111,79 159,80 177,26 190,81
8 21,80 25,40 48,00 40,25 59,62 65,73 63,83 96,82 51,09 216,68 192,40 45,60 193,87 196,33 200,80 192,39 210,43 211,29 242,74 244,04 234,75
9 25,05 27,74 52,04 44,25 65,53 71,54 71,45 107,15 55,23 228,35 204,10 49,18 211,86 211,27 212,43 209,88 225,30 227,96 245,28 244,41 237,00
10 26,51 36,69 172,77 20,95 131,98 44,17 65,17 87,33 192,68 80,57 106,96 38,29 83,15 86,58 97,98 25,64 92,06 127,00 114,00 164,65 225,49
13 42,80 33,03 72,05 45,93 67,09 42,10 36,99 117,16 175,59 67,22 90,79 55,47 109,53 117,84 105,45 148,68 91,63 105,77 164,59 181,40 233,06
4 10,70 17,96 10,08 9,43 17,01 19,41 15,45 21,42 31,19 38,17 66,64 49,67 51,42 52,21 67,65 114,95 46,59 61,31 123,11 141,43 207,03
7 48,18 10,35 27,86 27,18 22,85 61,77 13,86 25,63 102,71 31,66 45,54 69,21 31,25 53,94 37,39 184,22 24,72 91,86 42,59 52,34 196,67
12 42,37 26,69 25,99 35,38 31,01 46,94 37,27 94,12 94,20 20,05 39,54 57,18 60,48 45,69 33,95 46,72 26,45 137,36 72,12 39,64 99,06
15 9,24 1,00 4,16 16,46 1,00 28,59 1,00 6,43 20,16 4,87 0,25 19,24 39,73 39,70 33,80 47,78 11,48 117,07 37,17 14,25 134,54
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Supplemental Figure 1: Distribution of single phospho signals sorted by intensity of 33 
malignant TH and TC shows a very heterogenous distribution of RTK activity 
 
 
 
 
 
 
 
 
 
 
6 13 19 21 5 37 12 17 26 11 1 24 32 33 31 3 30 34 35
0
50
100
150
200
R
O
R
2
ROR2
ROR2
34 26 32 35 31 6 28 11 10 14 9 25 30 4 16 3 18 21 17
0
50
100
150
200
M
SP
 R
MSP R
MSP R
28 26 32 4 2 24 31 11 8 14 23 25 9 16 33 13 1 15 30
0
50
100
150
200
R
O
R
1
ROR1
ROR1
26 35 15 28 6 5 10 27 24 12 16 8 22 21 4 18 2 13 17
0
50
100
150
200
Ti
e-
2
Tie-2
Tie-2
2 32 26 36 20 29 8 30 28 5 3 7 16 9 15 25 19 13 12
0
50
100
150
200
D
tk
TYRO3
Dtk
31 5 4 27 2 29 14 8 19 22 6 37 21 17 34 7 13 23 30
0
50
100
150
200
In
su
lin
 R
Insulin R
Insulin R
23 7 15 20 16 12 17 9 3 30 8 4 25 32 22 26 31 37 10
0
50
100
150
200
M
uS
K
MuSK
MuSK
26 32 4 2 24 23 19 28 15 14 9 10 21 16 1 34 37 3 17
0
50
100
150
200
R
O
R
2
ROR2
ROR2
9 32 31 33 6 37 28 14 27 8 11 22 16 34 3 17 1 30 13
0
50
100
150
200
Tr
kA
TrkA
TrkA
23 34 32 31 33 6 12 19 37 27 24 9 17 7 18 21 30 2 13
0
50
100
150
200
VE
G
F 
R
1
VEGF R1
VEGF R1
12 26 32 4 14 27 29 2 22 8 34 11 18 23 10 16 1 7 6
0
50
100
150
200
M
-C
SF
 R
MCS FR
M-CSF R
29 34 5 20 31 6 28 19 22 24 11 25 10 35 16 7 21 2 13
0
50
100
150
200
PD
G
F 
R
 a
lp
ha
PDGF R alpha
PDGF R alpha
31 26 32 15 35 14 33 27 19 9 8 25 34 21 7 23 30 3 36
0
50
100
150
200
SC
F 
R
SCF R
SCF R
9 34 26 35 15 20 5 12 36 11 27 19 24 25 4 18 1 21 13
0
50
100
150
200
Tr
kB
TrkB
TrkB
14 27 26 35 15 20 5 22 4 36 24 11 17 10 28 16 1 2 13
0
50
100
150
200
VE
G
F 
R
2
VEGF R2
VEGF R2
26 32 35 31 23 37 29 9 11 25 27 34 10 3 22 17 19 30 36
0
50
100
150
200
M
er
MER
Mer
31 26 32 15 4 22 29 27 25 11 17 18 33 37 34 28 2 30 13
0
50
100
150
200
PD
G
F 
R
 b
et
a
PDGF R beta
PDGF R beta
27 30 32 35 36 13 34 19 15 33 9 17 3 21 22 23 5 37 1
0
50
100
150
200
Ti
e-
1
Tie-1
Tie-1
9 34 32 31 33 6 37 23 28 27 19 14 24 25 17 18 21 3 13
0
50
100
150
200
Tr
kC
TrkC
TrkC
20 29 32 31 22 37 30 8 27 6 11 33 28 10 21 18 7 23 13
0
50
100
150
200
VE
G
F 
R
3
VEGF R3
VEGF R3
supplemental Materials  
  60 
 
 
 
 
Supplemental Figure 2: Separate DMSO control (A) and sunitinib-treated (B) clusters 
were visualized (Supplemental Figures 2A and B, respectively). Visualization of 
unsupervised clustering of the ratio values (C). 
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Supplemental Figure 3: Unsupervised hierarchical clustering of ratio values of 
resistance-induced and native cell lines for SRI generation and validation. 
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Supplemental Figure 4: Upstream prediction of resistance-induced and native cell 
lines separated by the SRI. Final score of putatively affected kinases (y-axis). The 
specificity score is indicated by color. The length of the bars indicate the normalized 
specificity score (NSS) for these kinases (NSS < 0 indicates less inhibition, NSS > 0 
more inhibition in sunitinib-treated cells for the quantifier) (A). The corresponding 
volcano plot. Fond of the kinase indicates peptides included in the set (B). 
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Supplemental Figure 5: Unsupervised hierarchical clustering of ratio values of tissues 
for SRI generation and validation. 
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Supplemental Figure 6: Representative picture of the protocol used for PamChip 
analysis in the BioNavigatoR (version 6.2; PamGene, 's-Hertogenbosch, The 
Netherlands) 
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